代用合成血液の世界市場

代用合成血液の世界市場は2030年までに1,510万米ドルに達する見込み

2024年に920万米ドルと推定される代用合成血液の世界市場は、分析期間2024-2030年にCAGR 8.6%で成長し、2030年には1,510万米ドルに達すると予測されます。ヘモグロビンベースの酸素キャリアは、本レポートで分析したセグメントの1つであり、CAGRは10.4%を記録し、分析期間終了時には690万米ドルに達すると予測されています。パーフルオロカーボンエマルジョン分野の成長率は、分析期間中CAGR 5.8%と推定されます。

米国市場は250万米ドルと推定、中国はCAGR13.6%で成長予測

米国の代用合成血液市場は2024年に250万米ドルと推定されます。世界第2位の経済大国である中国は、2030年までに330万米ドルの市場規模に達すると予測され、分析期間2024-2030年のCAGRは13.6%です。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ4.2％と8.3％と予測されています。欧州では、ドイツがCAGR 5.7%で成長すると予測されています。

世界の代用合成血液市場- 主要動向と促進要因のまとめ

代用合成血液が医療分野で急成長している理由とは？

代用合成血液は、人間の血液が利用できなかったり適さない場合に、酸素運搬や体積拡張機能を果たすように設計された人工流体です。特に、外傷治療、戦場医療、および急速な血液喪失が生命を脅かす可能性のある外科的環境において価値があります。ドナー血液の利用可能性、保存の限界、感染症伝播のリスクといった課題がある中、合成代替血液は救命の可能性を提供します。

ヘモグロビンベースの酸素運搬体（HBOC）とパーフルオロカーボンエマルジョン（PFC）から成るこれらの代用品は、血液型検査、クロスマッチング、免疫拒絶反応の合併症を伴わずに、赤血球の主要な機能を再現するように開発されています。血液バンクが、特に低資源地域や災害被災地域において、持続的な血液不足に直面しているため、ヘルスケアシステムや防衛機関の間では、信頼性が高く、保存可能な合成代替品への関心が高まっています。

研究開発のブレークスルーは、代用血液の歴史的課題にどのように対処しているのか？

歴史的に、合成血液製剤は毒性、血管収縮、酸素供給量の制限による挫折に直面してきました。分子工学、カプセル化技術、組換えヘモグロビン生産における最近の進歩は、これらの障害を克服しつつあります。HBOCは現在、炎症反応を引き起こすことなく血行動態の安定性を維持するよう改良されています。高濃度の酸素を溶解できるPFCベースの代用品は、より優れた生体適合性とクリアランス率を目指して改良されています。

ナノテクノロジーを活用して、ヘモグロビンを脂質膜やポリマーに封入することで、毒性を軽減し、循環時間を延ばすことができます。凍結乾燥製剤や環境安定性製剤も開発中で、保存期間や現場での使用性を向上させています。これらの技術革新は、代用合成血液をより安全で効果的なものにし、臓器保存や虚血状態に対する酸素療法など、より幅広い臨床シナリオに適したものにしています。

臨床および施設における代用血液の需要はどこで増加しているか？

最も需要が高まっているのは、即座の輸血サポートが重要な外傷センター、軍事作戦、救急医療サービスです。戦場や遠隔地の環境では、血液の冷蔵保存や適合性試験が現実的でないため、合成代用品は拡張可能で輸送可能な代替品を提供します。

臓器移植、新生児医療、腫瘍学治療など、患者がしばしば著しい出血や免疫低下を経験する場面でも、合成酸素キャリアが採用されています。人道支援組織や災害対応部隊は、特に強固なドナー・システムがない地域において、大量死傷者発生時に合成酸素キャリアを試験的に使用しています。これらの使用事例は、多様な医療状況における人工血液の救命の可能性を強調しています。

代用合成血液市場の成長はいくつかの要因によって牽引されている...

万能酸素運搬体に対する需要の高まり、生物工学技術の進歩、ドナー血液の制限に対する世界の意識の高まりが市場を牽引しています。遺伝子組換えヘモグロビン合成とPFCナノエマルジョンにおける技術革新は、より安全で長く循環する代替血液を可能にしています。

政府の支援による研究開発資金、特に国防機関や宇宙機関が、初期段階の開発や臨床試験を後押ししています。発展途上諸国における外傷治療ネットワークや手術インフラの拡大により、保存期間が長く、周囲環境でも安定した代替血液に対する制度上の需要が生じています。ファスト・トラック指定やコンパッショネート・ユース・プログラムなどの規制の進展は、有望な候補品の迅速な市場参入を支えています。これらの要因が相まって、現代医療を変革するソリューションとしての人工血液の出現が加速しています。

セグメント

製品（ヘモグロビンベースの酸素運搬体、パーフルオロカーボンエマルジョン、幹細胞由来の赤血球、その他の製品）、供給源（ヒト血液供給源、微生物ベースの組み換えHB供給源、合成ポリマー供給源、幹細胞供給源、その他の供給源）、成分（赤血球代替物、血小板代替物、血漿代替物）;用途（心血管疾患用途、悪性新生物用途、傷害用途、新生児疾患用途、臓器移植用途、母体疾患用途、その他の用途）

調査対象企業の例

• Aurum Biosciences
• Boston Pharmaceuticals
• Boston Pharmaceuticals
• Centrum Medyczne VisusMed
• ErythroMer（KaloCyte）
• HbO2 Therapeutics（Hemopure）
• Hemarina（HEMOXYCarrier）
• HEMARINA SA
• Hemoglobin Oxygen Therapeutics LLC
• Hemoglobin Oxygen Therapeutics LLC
• NanoBlood LLC
• NuvOx Pharma
• OPK Biotech
• OPK Biotech LLC
• OXYVITA Inc
• Perftoran/Fluor02 Therapeutics
• Prolong Pharmaceuticals LLC
• SpheriTech Ltd.
• Vidophor（Fluor02 spin-off）

AIインテグレーション

Global Industry Analystsは、有効な専門家コンテンツとAIツールによって、市場情報と競合情報を変革しています。

Global Industry Analystsは、LLMや業界固有のSLMを照会する一般的な規範に従う代わりに、ビデオ記録、ブログ、検索エンジン調査、膨大な量の企業、製品/サービス、市場データなど、世界中の専門家から収集したコンテンツのリポジトリを構築しました。

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、売上原価（COGS）の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

• 市場概要
• 主要企業
• 市場動向と促進要因
• 世界市場の見通し

第3章 市場分析

• 米国
• カナダ
• 日本
• 中国
• 欧州
• フランス
• ドイツ
• イタリア
• 英国
• スペイン
• ロシア
• その他欧州
• アジア太平洋
• オーストラリア
• インド
• 韓国
• その他アジア太平洋地域
• ラテンアメリカ
• アルゼンチン
• ブラジル
• メキシコ
• その他ラテンアメリカ
• 中東
• イラン
• イスラエル
• サウジアラビア
• アラブ首長国連邦
• その他中東
• アフリカ

第4章 競合

Global Synthetic Blood Substitutes Market to Reach US$15.1 Million by 2030

The global market for Synthetic Blood Substitutes estimated at US$9.2 Million in the year 2024, is expected to reach US$15.1 Million by 2030, growing at a CAGR of 8.6% over the analysis period 2024-2030. Hemoglobin-based Oxygen Carriers, one of the segments analyzed in the report, is expected to record a 10.4% CAGR and reach US$6.9 Million by the end of the analysis period. Growth in the Perfluorocarbon Emulsions segment is estimated at 5.8% CAGR over the analysis period.

The U.S. Market is Estimated at US$2.5 Million While China is Forecast to Grow at 13.6% CAGR

The Synthetic Blood Substitutes market in the U.S. is estimated at US$2.5 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$3.3 Million by the year 2030 trailing a CAGR of 13.6% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 4.2% and 8.3% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 5.7% CAGR.

Global Synthetic Blood Substitutes Market - Key Trends & Drivers Summarized

Why Are Synthetic Blood Substitutes Gaining Urgency in Medical Science?

Synthetic blood substitutes are engineered fluids designed to perform oxygen-carrying and volume-expanding functions when human blood is unavailable or unsuitable. They are particularly valuable in trauma care, battlefield medicine, and surgical settings where rapid blood loss can be life-threatening. With challenges in donor blood availability, storage limitations, and the risk of infectious disease transmission, synthetic substitutes offer a potentially lifesaving alternative.

These substitutes-comprising hemoglobin-based oxygen carriers (HBOCs) and perfluorocarbon emulsions (PFCs)-are developed to replicate key functions of red blood cells without the complications of blood typing, cross-matching, or immune rejection. As blood banks face persistent shortages, particularly in low-resource and disaster-struck regions, interest in reliable, shelf-stable synthetic alternatives is intensifying among healthcare systems and defense agencies.

How Are R&D Breakthroughs Addressing Historical Challenges in Blood Substitutes?

Historically, synthetic blood products faced setbacks due to toxicity, vasoconstriction, and limited oxygen delivery. Recent advances in molecular engineering, encapsulation technologies, and recombinant hemoglobin production are overcoming these barriers. HBOCs are now being refined to maintain hemodynamic stability without triggering inflammatory responses. PFC-based substitutes, which can dissolve high levels of oxygen, are being modified for better biocompatibility and clearance rates.

Nanotechnology is being leveraged to encapsulate hemoglobin in lipid membranes or polymers to reduce toxicity and extend circulation time. Freeze-dried and ambient-stable formulations are under development, improving shelf life and field usability. These innovations are making synthetic blood substitutes safer, more effective, and suitable for a wider range of clinical scenarios, including organ preservation and oxygen therapy for ischemic conditions.

Where Is Clinical and Institutional Demand for Blood Substitutes Increasing?

The highest demand is emerging from trauma centers, military operations, and emergency medical services where immediate transfusion support is critical. In battlefield and remote settings, where blood refrigeration and compatibility testing are impractical, synthetic substitutes offer a scalable and transportable alternative.

Organ transplantation procedures, neonatal care, and oncology treatments-where patients often experience significant blood loss or immune compromise-are also adopting synthetic oxygen carriers. Humanitarian organizations and disaster response units are piloting synthetic substitutes in mass casualty events, particularly in regions lacking robust donor systems. These use cases underscore the life-saving potential of synthetic blood in diverse medical contexts.

The Growth in the Synthetic Blood Substitutes Market Is Driven by Several Factors…

It is driven by rising demand for universal oxygen carriers, advancements in bioengineering technologies, and increasing global awareness of donor blood limitations. Innovations in recombinant hemoglobin synthesis and PFC nanoemulsions are enabling safer and longer-circulating blood alternatives.

Government-backed research funding, particularly from defense and space agencies, is catalyzing early-stage development and clinical trials. Expanding trauma care networks and surgical infrastructure in developing countries are generating institutional demand for blood alternatives with long shelf life and ambient stability. Regulatory progress, including fast-track designations and compassionate-use programs, is supporting faster market entry for promising candidates. Together, these factors are accelerating the emergence of synthetic blood as a transformative solution in modern medicine.

SCOPE OF STUDY:

The report analyzes the Synthetic Blood Substitutes market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Product (Hemoglobin-based Oxygen Carriers, Perfluorocarbon Emulsions, Stem Cell-Derived Red Blood Cells, Other Products); Source (Human Blood Source, Microorganism Based Recombinant HB Source, Synthetic Polymers Source, Stem Cells Source, Other Sources); Component (Red Blood Cell Substitutes, Platelet Substitutes, Plasma Substitutes); Application (Cardiovascular Disease Application, Malignant Neoplasma Application, Injuries Application, Neonatal Conditions Application, Organ Transplant Application, Maternal Condition Application, Other Applications)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 44 Featured) -

• Aurum Biosciences
• Boston Pharmaceuticals
• Boston Pharmaceuticals
• Centrum Medyczne VisusMed
• ErythroMer (KaloCyte)
• HbO2 Therapeutics (Hemopure)
• Hemarina (HEMOXYCarrier)
• HEMARINA SA
• Hemoglobin Oxygen Therapeutics LLC
• Hemoglobin Oxygen Therapeutics LLC
• NanoBlood LLC
• NuvOx Pharma
• OPK Biotech
• OPK Biotech LLC
• OXYVITA Inc
• Perftoran / Fluor02 Therapeutics
• Prolong Pharmaceuticals LLC
• SpheriTech Ltd.
• Vidophor (Fluor02 spin-off)

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

• 1. MARKET OVERVIEW
  • Influencer Market Insights
  • World Market Trajectories
  • Tariff Impact on Global Supply Chain Patterns
  • Synthetic Blood Substitutes - Global Key Competitors Percentage Market Share in 2025 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
• 2. FOCUS ON SELECT PLAYERS
• 3. MARKET TRENDS & DRIVERS
  • Rising Demand for Emergency Blood Replacement in Trauma and Military Settings Drives Market Growth
  • Shortages in Donor Blood Supply Highlight the Need for Synthetic Oxygen Carriers
  • Expansion of Surgical Procedures in Remote or Resource-Limited Areas Spurs Demand for Shelf-Stable Alternatives
  • Technological Advancements in Hemoglobin-Based Oxygen Carriers Enhance Product Efficacy and Safety
  • Increased R&D in Artificial Red Blood Cells Fuels Development of Next-Gen Substitutes
  • Growth in Transfusion-Free Surgeries Strengthens Business Case for Synthetic Blood Options
  • Rising Incidence of Hemorrhagic Shock and Blood Disorders Expands Clinical Use Cases
  • Regulatory Interest in Preparedness for Mass Casualty and Disaster Scenarios Drives Market Validation
  • Demand for Universal Compatibility and Reduced Risk of Disease Transmission Enhances Appeal
  • Expansion of Pre-Hospital Emergency Care Systems Spurs Portable Blood Substitute Deployment
  • Military and Aerospace Medicine Applications Drive Interest in Low-Volume, High-Efficacy Substitutes
  • Growth in Geriatric Surgeries With Higher Bleeding Risk Elevates Clinical Utility of Blood Alternatives
• 4. GLOBAL MARKET PERSPECTIVE
  • TABLE 1: World Synthetic Blood Substitutes Market Analysis of Annual Sales in US$ for Years 2014 through 2030
  • TABLE 2: World Recent Past, Current & Future Analysis for Synthetic Blood Substitutes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
  • TABLE 3: World Historic Review for Synthetic Blood Substitutes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
  • TABLE 4: World 16-Year Perspective for Synthetic Blood Substitutes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2025 & 2030
  • TABLE 5: World Recent Past, Current & Future Analysis for Hemoglobin-based Oxygen Carriers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
  • TABLE 6: World Historic Review for Hemoglobin-based Oxygen Carriers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
  • TABLE 7: World 16-Year Perspective for Hemoglobin-based Oxygen Carriers by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 8: World Recent Past, Current & Future Analysis for Perfluorocarbon Emulsions by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
  • TABLE 9: World Historic Review for Perfluorocarbon Emulsions by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
  • TABLE 10: World 16-Year Perspective for Perfluorocarbon Emulsions by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 11: World Recent Past, Current & Future Analysis for Stem Cell-Derived Red Blood Cells by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
  • TABLE 12: World Historic Review for Stem Cell-Derived Red Blood Cells by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
  • TABLE 13: World 16-Year Perspective for Stem Cell-Derived Red Blood Cells by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 14: World Recent Past, Current & Future Analysis for Other Products by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
  • TABLE 15: World Historic Review for Other Products by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
  • TABLE 16: World 16-Year Perspective for Other Products by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 17: World Recent Past, Current & Future Analysis for Red Blood Cell Substitutes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
  • TABLE 18: World Historic Review for Red Blood Cell Substitutes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
  • TABLE 19: World 16-Year Perspective for Red Blood Cell Substitutes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 20: World Recent Past, Current & Future Analysis for Platelet Substitutes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
  • TABLE 21: World Historic Review for Platelet Substitutes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
  • TABLE 22: World 16-Year Perspective for Platelet Substitutes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 23: World Recent Past, Current & Future Analysis for Plasma Substitutes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
  • TABLE 24: World Historic Review for Plasma Substitutes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
  • TABLE 25: World 16-Year Perspective for Plasma Substitutes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 26: World Recent Past, Current & Future Analysis for Cardiovascular Disease Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
  • TABLE 27: World Historic Review for Cardiovascular Disease Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
  • TABLE 28: World 16-Year Perspective for Cardiovascular Disease Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 29: World Recent Past, Current & Future Analysis for Malignant Neoplasma Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
  • TABLE 30: World Historic Review for Malignant Neoplasma Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
  • TABLE 31: World 16-Year Perspective for Malignant Neoplasma Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 32: World Recent Past, Current & Future Analysis for Injuries Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
  • TABLE 33: World Historic Review for Injuries Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
  • TABLE 34: World 16-Year Perspective for Injuries Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 35: World Recent Past, Current & Future Analysis for Neonatal Conditions Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
  • TABLE 36: World Historic Review for Neonatal Conditions Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
  • TABLE 37: World 16-Year Perspective for Neonatal Conditions Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 38: World Recent Past, Current & Future Analysis for Organ Transplant Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
  • TABLE 39: World Historic Review for Organ Transplant Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
  • TABLE 40: World 16-Year Perspective for Organ Transplant Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 41: World Recent Past, Current & Future Analysis for Maternal Condition Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
  • TABLE 42: World Historic Review for Maternal Condition Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
  • TABLE 43: World 16-Year Perspective for Maternal Condition Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 44: World Recent Past, Current & Future Analysis for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
  • TABLE 45: World Historic Review for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
  • TABLE 46: World 16-Year Perspective for Other Applications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 47: World Recent Past, Current & Future Analysis for Human Blood Source by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
  • TABLE 48: World Historic Review for Human Blood Source by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
  • TABLE 49: World 16-Year Perspective for Human Blood Source by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 50: World Recent Past, Current & Future Analysis for Microorganism Based Recombinant HB Source by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
  • TABLE 51: World Historic Review for Microorganism Based Recombinant HB Source by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
  • TABLE 52: World 16-Year Perspective for Microorganism Based Recombinant HB Source by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 53: World Recent Past, Current & Future Analysis for Synthetic Polymers Source by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
  • TABLE 54: World Historic Review for Synthetic Polymers Source by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
  • TABLE 55: World 16-Year Perspective for Synthetic Polymers Source by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 56: World Recent Past, Current & Future Analysis for Stem Cells Source by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
  • TABLE 57: World Historic Review for Stem Cells Source by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
  • TABLE 58: World 16-Year Perspective for Stem Cells Source by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 59: World Recent Past, Current & Future Analysis for Other Sources by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
  • TABLE 60: World Historic Review for Other Sources by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
  • TABLE 61: World 16-Year Perspective for Other Sources by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030

III. MARKET ANALYSIS

• UNITED STATES
  • Synthetic Blood Substitutes Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
  • TABLE 62: USA Recent Past, Current & Future Analysis for Synthetic Blood Substitutes by Product - Hemoglobin-based Oxygen Carriers, Perfluorocarbon Emulsions, Stem Cell-Derived Red Blood Cells and Other Products - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 63: USA Historic Review for Synthetic Blood Substitutes by Product - Hemoglobin-based Oxygen Carriers, Perfluorocarbon Emulsions, Stem Cell-Derived Red Blood Cells and Other Products Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
  • TABLE 64: USA 16-Year Perspective for Synthetic Blood Substitutes by Product - Percentage Breakdown of Value Sales for Hemoglobin-based Oxygen Carriers, Perfluorocarbon Emulsions, Stem Cell-Derived Red Blood Cells and Other Products for the Years 2014, 2025 & 2030
  • TABLE 65: USA Recent Past, Current & Future Analysis for Synthetic Blood Substitutes by Component - Red Blood Cell Substitutes, Platelet Substitutes and Plasma Substitutes - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 66: USA Historic Review for Synthetic Blood Substitutes by Component - Red Blood Cell Substitutes, Platelet Substitutes and Plasma Substitutes Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
  • TABLE 67: USA 16-Year Perspective for Synthetic Blood Substitutes by Component - Percentage Breakdown of Value Sales for Red Blood Cell Substitutes, Platelet Substitutes and Plasma Substitutes for the Years 2014, 2025 & 2030
  • TABLE 68: USA Recent Past, Current & Future Analysis for Synthetic Blood Substitutes by Application - Cardiovascular Disease Application, Malignant Neoplasma Application, Injuries Application, Neonatal Conditions Application, Organ Transplant Application, Maternal Condition Application and Other Applications - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 69: USA Historic Review for Synthetic Blood Substitutes by Application - Cardiovascular Disease Application, Malignant Neoplasma Application, Injuries Application, Neonatal Conditions Application, Organ Transplant Application, Maternal Condition Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
  • TABLE 70: USA 16-Year Perspective for Synthetic Blood Substitutes by Application - Percentage Breakdown of Value Sales for Cardiovascular Disease Application, Malignant Neoplasma Application, Injuries Application, Neonatal Conditions Application, Organ Transplant Application, Maternal Condition Application and Other Applications for the Years 2014, 2025 & 2030
  • TABLE 71: USA Recent Past, Current & Future Analysis for Synthetic Blood Substitutes by Source - Human Blood Source, Microorganism Based Recombinant HB Source, Synthetic Polymers Source, Stem Cells Source and Other Sources - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 72: USA Historic Review for Synthetic Blood Substitutes by Source - Human Blood Source, Microorganism Based Recombinant HB Source, Synthetic Polymers Source, Stem Cells Source and Other Sources Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
  • TABLE 73: USA 16-Year Perspective for Synthetic Blood Substitutes by Source - Percentage Breakdown of Value Sales for Human Blood Source, Microorganism Based Recombinant HB Source, Synthetic Polymers Source, Stem Cells Source and Other Sources for the Years 2014, 2025 & 2030
• CANADA
  • TABLE 74: Canada Recent Past, Current & Future Analysis for Synthetic Blood Substitutes by Product - Hemoglobin-based Oxygen Carriers, Perfluorocarbon Emulsions, Stem Cell-Derived Red Blood Cells and Other Products - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 75: Canada Historic Review for Synthetic Blood Substitutes by Product - Hemoglobin-based Oxygen Carriers, Perfluorocarbon Emulsions, Stem Cell-Derived Red Blood Cells and Other Products Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
  • TABLE 76: Canada 16-Year Perspective for Synthetic Blood Substitutes by Product - Percentage Breakdown of Value Sales for Hemoglobin-based Oxygen Carriers, Perfluorocarbon Emulsions, Stem Cell-Derived Red Blood Cells and Other Products for the Years 2014, 2025 & 2030
  • TABLE 77: Canada Recent Past, Current & Future Analysis for Synthetic Blood Substitutes by Component - Red Blood Cell Substitutes, Platelet Substitutes and Plasma Substitutes - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 78: Canada Historic Review for Synthetic Blood Substitutes by Component - Red Blood Cell Substitutes, Platelet Substitutes and Plasma Substitutes Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
  • TABLE 79: Canada 16-Year Perspective for Synthetic Blood Substitutes by Component - Percentage Breakdown of Value Sales for Red Blood Cell Substitutes, Platelet Substitutes and Plasma Substitutes for the Years 2014, 2025 & 2030
  • TABLE 80: Canada Recent Past, Current & Future Analysis for Synthetic Blood Substitutes by Application - Cardiovascular Disease Application, Malignant Neoplasma Application, Injuries Application, Neonatal Conditions Application, Organ Transplant Application, Maternal Condition Application and Other Applications - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 81: Canada Historic Review for Synthetic Blood Substitutes by Application - Cardiovascular Disease Application, Malignant Neoplasma Application, Injuries Application, Neonatal Conditions Application, Organ Transplant Application, Maternal Condition Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
  • TABLE 82: Canada 16-Year Perspective for Synthetic Blood Substitutes by Application - Percentage Breakdown of Value Sales for Cardiovascular Disease Application, Malignant Neoplasma Application, Injuries Application, Neonatal Conditions Application, Organ Transplant Application, Maternal Condition Application and Other Applications for the Years 2014, 2025 & 2030
  • TABLE 83: Canada Recent Past, Current & Future Analysis for Synthetic Blood Substitutes by Source - Human Blood Source, Microorganism Based Recombinant HB Source, Synthetic Polymers Source, Stem Cells Source and Other Sources - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 84: Canada Historic Review for Synthetic Blood Substitutes by Source - Human Blood Source, Microorganism Based Recombinant HB Source, Synthetic Polymers Source, Stem Cells Source and Other Sources Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
  • TABLE 85: Canada 16-Year Perspective for Synthetic Blood Substitutes by Source - Percentage Breakdown of Value Sales for Human Blood Source, Microorganism Based Recombinant HB Source, Synthetic Polymers Source, Stem Cells Source and Other Sources for the Years 2014, 2025 & 2030
• JAPAN
  • Synthetic Blood Substitutes Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
  • TABLE 86: Japan Recent Past, Current & Future Analysis for Synthetic Blood Substitutes by Product - Hemoglobin-based Oxygen Carriers, Perfluorocarbon Emulsions, Stem Cell-Derived Red Blood Cells and Other Products - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 87: Japan Historic Review for Synthetic Blood Substitutes by Product - Hemoglobin-based Oxygen Carriers, Perfluorocarbon Emulsions, Stem Cell-Derived Red Blood Cells and Other Products Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
  • TABLE 88: Japan 16-Year Perspective for Synthetic Blood Substitutes by Product - Percentage Breakdown of Value Sales for Hemoglobin-based Oxygen Carriers, Perfluorocarbon Emulsions, Stem Cell-Derived Red Blood Cells and Other Products for the Years 2014, 2025 & 2030
  • TABLE 89: Japan Recent Past, Current & Future Analysis for Synthetic Blood Substitutes by Component - Red Blood Cell Substitutes, Platelet Substitutes and Plasma Substitutes - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 90: Japan Historic Review for Synthetic Blood Substitutes by Component - Red Blood Cell Substitutes, Platelet Substitutes and Plasma Substitutes Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
  • TABLE 91: Japan 16-Year Perspective for Synthetic Blood Substitutes by Component - Percentage Breakdown of Value Sales for Red Blood Cell Substitutes, Platelet Substitutes and Plasma Substitutes for the Years 2014, 2025 & 2030
  • TABLE 92: Japan Recent Past, Current & Future Analysis for Synthetic Blood Substitutes by Application - Cardiovascular Disease Application, Malignant Neoplasma Application, Injuries Application, Neonatal Conditions Application, Organ Transplant Application, Maternal Condition Application and Other Applications - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 93: Japan Historic Review for Synthetic Blood Substitutes by Application - Cardiovascular Disease Application, Malignant Neoplasma Application, Injuries Application, Neonatal Conditions Application, Organ Transplant Application, Maternal Condition Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
  • TABLE 94: Japan 16-Year Perspective for Synthetic Blood Substitutes by Application - Percentage Breakdown of Value Sales for Cardiovascular Disease Application, Malignant Neoplasma Application, Injuries Application, Neonatal Conditions Application, Organ Transplant Application, Maternal Condition Application and Other Applications for the Years 2014, 2025 & 2030
  • TABLE 95: Japan Recent Past, Current & Future Analysis for Synthetic Blood Substitutes by Source - Human Blood Source, Microorganism Based Recombinant HB Source, Synthetic Polymers Source, Stem Cells Source and Other Sources - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 96: Japan Historic Review for Synthetic Blood Substitutes by Source - Human Blood Source, Microorganism Based Recombinant HB Source, Synthetic Polymers Source, Stem Cells Source and Other Sources Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
  • TABLE 97: Japan 16-Year Perspective for Synthetic Blood Substitutes by Source - Percentage Breakdown of Value Sales for Human Blood Source, Microorganism Based Recombinant HB Source, Synthetic Polymers Source, Stem Cells Source and Other Sources for the Years 2014, 2025 & 2030
• CHINA
  • Synthetic Blood Substitutes Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
  • TABLE 98: China Recent Past, Current & Future Analysis for Synthetic Blood Substitutes by Product - Hemoglobin-based Oxygen Carriers, Perfluorocarbon Emulsions, Stem Cell-Derived Red Blood Cells and Other Products - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 99: China Historic Review for Synthetic Blood Substitutes by Product - Hemoglobin-based Oxygen Carriers, Perfluorocarbon Emulsions, Stem Cell-Derived Red Blood Cells and Other Products Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
  • TABLE 100: China 16-Year Perspective for Synthetic Blood Substitutes by Product - Percentage Breakdown of Value Sales for Hemoglobin-based Oxygen Carriers, Perfluorocarbon Emulsions, Stem Cell-Derived Red Blood Cells and Other Products for the Years 2014, 2025 & 2030
  • TABLE 101: China Recent Past, Current & Future Analysis for Synthetic Blood Substitutes by Component - Red Blood Cell Substitutes, Platelet Substitutes and Plasma Substitutes - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 102: China Historic Review for Synthetic Blood Substitutes by Component - Red Blood Cell Substitutes, Platelet Substitutes and Plasma Substitutes Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
  • TABLE 103: China 16-Year Perspective for Synthetic Blood Substitutes by Component - Percentage Breakdown of Value Sales for Red Blood Cell Substitutes, Platelet Substitutes and Plasma Substitutes for the Years 2014, 2025 & 2030
  • TABLE 104: China Recent Past, Current & Future Analysis for Synthetic Blood Substitutes by Application - Cardiovascular Disease Application, Malignant Neoplasma Application, Injuries Application, Neonatal Conditions Application, Organ Transplant Application, Maternal Condition Application and Other Applications - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 105: China Historic Review for Synthetic Blood Substitutes by Application - Cardiovascular Disease Application, Malignant Neoplasma Application, Injuries Application, Neonatal Conditions Application, Organ Transplant Application, Maternal Condition Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
  • TABLE 106: China 16-Year Perspective for Synthetic Blood Substitutes by Application - Percentage Breakdown of Value Sales for Cardiovascular Disease Application, Malignant Neoplasma Application, Injuries Application, Neonatal Conditions Application, Organ Transplant Application, Maternal Condition Application and Other Applications for the Years 2014, 2025 & 2030
  • TABLE 107: China Recent Past, Current & Future Analysis for Synthetic Blood Substitutes by Source - Human Blood Source, Microorganism Based Recombinant HB Source, Synthetic Polymers Source, Stem Cells Source and Other Sources - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 108: China Historic Review for Synthetic Blood Substitutes by Source - Human Blood Source, Microorganism Based Recombinant HB Source, Synthetic Polymers Source, Stem Cells Source and Other Sources Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
  • TABLE 109: China 16-Year Perspective for Synthetic Blood Substitutes by Source - Percentage Breakdown of Value Sales for Human Blood Source, Microorganism Based Recombinant HB Source, Synthetic Polymers Source, Stem Cells Source and Other Sources for the Years 2014, 2025 & 2030
• EUROPE
  • Synthetic Blood Substitutes Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
  • TABLE 110: Europe Recent Past, Current & Future Analysis for Synthetic Blood Substitutes by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
  • TABLE 111: Europe Historic Review for Synthetic Blood Substitutes by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
  • TABLE 112: Europe 16-Year Perspective for Synthetic Blood Substitutes by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2025 & 2030
  • TABLE 113: Europe Recent Past, Current & Future Analysis for Synthetic Blood Substitutes by Product - Hemoglobin-based Oxygen Carriers, Perfluorocarbon Emulsions, Stem Cell-Derived Red Blood Cells and Other Products - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 114: Europe Historic Review for Synthetic Blood Substitutes by Product - Hemoglobin-based Oxygen Carriers, Perfluorocarbon Emulsions, Stem Cell-Derived Red Blood Cells and Other Products Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
  • TABLE 115: Europe 16-Year Perspective for Synthetic Blood Substitutes by Product - Percentage Breakdown of Value Sales for Hemoglobin-based Oxygen Carriers, Perfluorocarbon Emulsions, Stem Cell-Derived Red Blood Cells and Other Products for the Years 2014, 2025 & 2030
  • TABLE 116: Europe Recent Past, Current & Future Analysis for Synthetic Blood Substitutes by Component - Red Blood Cell Substitutes, Platelet Substitutes and Plasma Substitutes - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 117: Europe Historic Review for Synthetic Blood Substitutes by Component - Red Blood Cell Substitutes, Platelet Substitutes and Plasma Substitutes Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
  • TABLE 118: Europe 16-Year Perspective for Synthetic Blood Substitutes by Component - Percentage Breakdown of Value Sales for Red Blood Cell Substitutes, Platelet Substitutes and Plasma Substitutes for the Years 2014, 2025 & 2030
  • TABLE 119: Europe Recent Past, Current & Future Analysis for Synthetic Blood Substitutes by Application - Cardiovascular Disease Application, Malignant Neoplasma Application, Injuries Application, Neonatal Conditions Application, Organ Transplant Application, Maternal Condition Application and Other Applications - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 120: Europe Historic Review for Synthetic Blood Substitutes by Application - Cardiovascular Disease Application, Malignant Neoplasma Application, Injuries Application, Neonatal Conditions Application, Organ Transplant Application, Maternal Condition Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
  • TABLE 121: Europe 16-Year Perspective for Synthetic Blood Substitutes by Application - Percentage Breakdown of Value Sales for Cardiovascular Disease Application, Malignant Neoplasma Application, Injuries Application, Neonatal Conditions Application, Organ Transplant Application, Maternal Condition Application and Other Applications for the Years 2014, 2025 & 2030
  • TABLE 122: Europe Recent Past, Current & Future Analysis for Synthetic Blood Substitutes by Source - Human Blood Source, Microorganism Based Recombinant HB Source, Synthetic Polymers Source, Stem Cells Source and Other Sources - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 123: Europe Historic Review for Synthetic Blood Substitutes by Source - Human Blood Source, Microorganism Based Recombinant HB Source, Synthetic Polymers Source, Stem Cells Source and Other Sources Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
  • TABLE 124: Europe 16-Year Perspective for Synthetic Blood Substitutes by Source - Percentage Breakdown of Value Sales for Human Blood Source, Microorganism Based Recombinant HB Source, Synthetic Polymers Source, Stem Cells Source and Other Sources for the Years 2014, 2025 & 2030
• FRANCE
  • Synthetic Blood Substitutes Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
  • TABLE 125: France Recent Past, Current & Future Analysis for Synthetic Blood Substitutes by Product - Hemoglobin-based Oxygen Carriers, Perfluorocarbon Emulsions, Stem Cell-Derived Red Blood Cells and Other Products - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 126: France Historic Review for Synthetic Blood Substitutes by Product - Hemoglobin-based Oxygen Carriers, Perfluorocarbon Emulsions, Stem Cell-Derived Red Blood Cells and Other Products Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
  • TABLE 127: France 16-Year Perspective for Synthetic Blood Substitutes by Product - Percentage Breakdown of Value Sales for Hemoglobin-based Oxygen Carriers, Perfluorocarbon Emulsions, Stem Cell-Derived Red Blood Cells and Other Products for the Years 2014, 2025 & 2030
  • TABLE 128: France Recent Past, Current & Future Analysis for Synthetic Blood Substitutes by Component - Red Blood Cell Substitutes, Platelet Substitutes and Plasma Substitutes - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 129: France Historic Review for Synthetic Blood Substitutes by Component - Red Blood Cell Substitutes, Platelet Substitutes and Plasma Substitutes Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
  • TABLE 130: France 16-Year Perspective for Synthetic Blood Substitutes by Component - Percentage Breakdown of Value Sales for Red Blood Cell Substitutes, Platelet Substitutes and Plasma Substitutes for the Years 2014, 2025 & 2030
  • TABLE 131: France Recent Past, Current & Future Analysis for Synthetic Blood Substitutes by Application - Cardiovascular Disease Application, Malignant Neoplasma Application, Injuries Application, Neonatal Conditions Application, Organ Transplant Application, Maternal Condition Application and Other Applications - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 132: France Historic Review for Synthetic Blood Substitutes by Application - Cardiovascular Disease Application, Malignant Neoplasma Application, Injuries Application, Neonatal Conditions Application, Organ Transplant Application, Maternal Condition Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
  • TABLE 133: France 16-Year Perspective for Synthetic Blood Substitutes by Application - Percentage Breakdown of Value Sales for Cardiovascular Disease Application, Malignant Neoplasma Application, Injuries Application, Neonatal Conditions Application, Organ Transplant Application, Maternal Condition Application and Other Applications for the Years 2014, 2025 & 2030
  • TABLE 134: France Recent Past, Current & Future Analysis for Synthetic Blood Substitutes by Source - Human Blood Source, Microorganism Based Recombinant HB Source, Synthetic Polymers Source, Stem Cells Source and Other Sources - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 135: France Historic Review for Synthetic Blood Substitutes by Source - Human Blood Source, Microorganism Based Recombinant HB Source, Synthetic Polymers Source, Stem Cells Source and Other Sources Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
  • TABLE 136: France 16-Year Perspective for Synthetic Blood Substitutes by Source - Percentage Breakdown of Value Sales for Human Blood Source, Microorganism Based Recombinant HB Source, Synthetic Polymers Source, Stem Cells Source and Other Sources for the Years 2014, 2025 & 2030
• GERMANY
  • Synthetic Blood Substitutes Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
  • TABLE 137: Germany Recent Past, Current & Future Analysis for Synthetic Blood Substitutes by Product - Hemoglobin-based Oxygen Carriers, Perfluorocarbon Emulsions, Stem Cell-Derived Red Blood Cells and Other Products - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 138: Germany Historic Review for Synthetic Blood Substitutes by Product - Hemoglobin-based Oxygen Carriers, Perfluorocarbon Emulsions, Stem Cell-Derived Red Blood Cells and Other Products Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
  • TABLE 139: Germany 16-Year Perspective for Synthetic Blood Substitutes by Product - Percentage Breakdown of Value Sales for Hemoglobin-based Oxygen Carriers, Perfluorocarbon Emulsions, Stem Cell-Derived Red Blood Cells and Other Products for the Years 2014, 2025 & 2030
  • TABLE 140: Germany Recent Past, Current & Future Analysis for Synthetic Blood Substitutes by Component - Red Blood Cell Substitutes, Platelet Substitutes and Plasma Substitutes - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 141: Germany Historic Review for Synthetic Blood Substitutes by Component - Red Blood Cell Substitutes, Platelet Substitutes and Plasma Substitutes Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
  • TABLE 142: Germany 16-Year Perspective for Synthetic Blood Substitutes by Component - Percentage Breakdown of Value Sales for Red Blood Cell Substitutes, Platelet Substitutes and Plasma Substitutes for the Years 2014, 2025 & 2030
  • TABLE 143: Germany Recent Past, Current & Future Analysis for Synthetic Blood Substitutes by Application - Cardiovascular Disease Application, Malignant Neoplasma Application, Injuries Application, Neonatal Conditions Application, Organ Transplant Application, Maternal Condition Application and Other Applications - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 144: Germany Historic Review for Synthetic Blood Substitutes by Application - Cardiovascular Disease Application, Malignant Neoplasma Application, Injuries Application, Neonatal Conditions Application, Organ Transplant Application, Maternal Condition Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
  • TABLE 145: Germany 16-Year Perspective for Synthetic Blood Substitutes by Application - Percentage Breakdown of Value Sales for Cardiovascular Disease Application, Malignant Neoplasma Application, Injuries Application, Neonatal Conditions Application, Organ Transplant Application, Maternal Condition Application and Other Applications for the Years 2014, 2025 & 2030
  • TABLE 146: Germany Recent Past, Current & Future Analysis for Synthetic Blood Substitutes by Source - Human Blood Source, Microorganism Based Recombinant HB Source, Synthetic Polymers Source, Stem Cells Source and Other Sources - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 147: Germany Historic Review for Synthetic Blood Substitutes by Source - Human Blood Source, Microorganism Based Recombinant HB Source, Synthetic Polymers Source, Stem Cells Source and Other Sources Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
  • TABLE 148: Germany 16-Year Perspective for Synthetic Blood Substitutes by Source - Percentage Breakdown of Value Sales for Human Blood Source, Microorganism Based Recombinant HB Source, Synthetic Polymers Source, Stem Cells Source and Other Sources for the Years 2014, 2025 & 2030
• ITALY
  • TABLE 149: Italy Recent Past, Current & Future Analysis for Synthetic Blood Substitutes by Product - Hemoglobin-based Oxygen Carriers, Perfluorocarbon Emulsions, Stem Cell-Derived Red Blood Cells and Other Products - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 150: Italy Historic Review for Synthetic Blood Substitutes by Product - Hemoglobin-based Oxygen Carriers, Perfluorocarbon Emulsions, Stem Cell-Derived Red Blood Cells and Other Products Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
  • TABLE 151: Italy 16-Year Perspective for Synthetic Blood Substitutes by Product - Percentage Breakdown of Value Sales for Hemoglobin-based Oxygen Carriers, Perfluorocarbon Emulsions, Stem Cell-Derived Red Blood Cells and Other Products for the Years 2014, 2025 & 2030
  • TABLE 152: Italy Recent Past, Current & Future Analysis for Synthetic Blood Substitutes by Component - Red Blood Cell Substitutes, Platelet Substitutes and Plasma Substitutes - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 153: Italy Historic Review for Synthetic Blood Substitutes by Component - Red Blood Cell Substitutes, Platelet Substitutes and Plasma Substitutes Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
  • TABLE 154: Italy 16-Year Perspective for Synthetic Blood Substitutes by Component - Percentage Breakdown of Value Sales for Red Blood Cell Substitutes, Platelet Substitutes and Plasma Substitutes for the Years 2014, 2025 & 2030
  • TABLE 155: Italy Recent Past, Current & Future Analysis for Synthetic Blood Substitutes by Application - Cardiovascular Disease Application, Malignant Neoplasma Application, Injuries Application, Neonatal Conditions Application, Organ Transplant Application, Maternal Condition Application and Other Applications - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 156: Italy Historic Review for Synthetic Blood Substitutes by Application - Cardiovascular Disease Application, Malignant Neoplasma Application, Injuries Application, Neonatal Conditions Application, Organ Transplant Application, Maternal Condition Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
  • TABLE 157: Italy 16-Year Perspective for Synthetic Blood Substitutes by Application - Percentage Breakdown of Value Sales for Cardiovascular Disease Application, Malignant Neoplasma Application, Injuries Application, Neonatal Conditions Application, Organ Transplant Application, Maternal Condition Application and Other Applications for the Years 2014, 2025 & 2030
  • TABLE 158: Italy Recent Past, Current & Future Analysis for Synthetic Blood Substitutes by Source - Human Blood Source, Microorganism Based Recombinant HB Source, Synthetic Polymers Source, Stem Cells Source and Other Sources - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 159: Italy Historic Review for Synthetic Blood Substitutes by Source - Human Blood Source, Microorganism Based Recombinant HB Source, Synthetic Polymers Source, Stem Cells Source and Other Sources Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
  • TABLE 160: Italy 16-Year Perspective for Synthetic Blood Substitutes by Source - Percentage Breakdown of Value Sales for Human Blood Source, Microorganism Based Recombinant HB Source, Synthetic Polymers Source, Stem Cells Source and Other Sources for the Years 2014, 2025 & 2030
• UNITED KINGDOM
  • Synthetic Blood Substitutes Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
  • TABLE 161: UK Recent Past, Current & Future Analysis for Synthetic Blood Substitutes by Product - Hemoglobin-based Oxygen Carriers, Perfluorocarbon Emulsions, Stem Cell-Derived Red Blood Cells and Other Products - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 162: UK Historic Review for Synthetic Blood Substitutes by Product - Hemoglobin-based Oxygen Carriers, Perfluorocarbon Emulsions, Stem Cell-Derived Red Blood Cells and Other Products Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
  • TABLE 163: UK 16-Year Perspective for Synthetic Blood Substitutes by Product - Percentage Breakdown of Value Sales for Hemoglobin-based Oxygen Carriers, Perfluorocarbon Emulsions, Stem Cell-Derived Red Blood Cells and Other Products for the Years 2014, 2025 & 2030
  • TABLE 164: UK Recent Past, Current & Future Analysis for Synthetic Blood Substitutes by Component - Red Blood Cell Substitutes, Platelet Substitutes and Plasma Substitutes - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 165: UK Historic Review for Synthetic Blood Substitutes by Component - Red Blood Cell Substitutes, Platelet Substitutes and Plasma Substitutes Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
  • TABLE 166: UK 16-Year Perspective for Synthetic Blood Substitutes by Component - Percentage Breakdown of Value Sales for Red Blood Cell Substitutes, Platelet Substitutes and Plasma Substitutes for the Years 2014, 2025 & 2030
  • TABLE 167: UK Recent Past, Current & Future Analysis for Synthetic Blood Substitutes by Application - Cardiovascular Disease Application, Malignant Neoplasma Application, Injuries Application, Neonatal Conditions Application, Organ Transplant Application, Maternal Condition Application and Other Applications - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 168: UK Historic Review for Synthetic Blood Substitutes by Application - Cardiovascular Disease Application, Malignant Neoplasma Application, Injuries Application, Neonatal Conditions Application, Organ Transplant Application, Maternal Condition Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
  • TABLE 169: UK 16-Year Perspective for Synthetic Blood Substitutes by Application - Percentage Breakdown of Value Sales for Cardiovascular Disease Application, Malignant Neoplasma Application, Injuries Application, Neonatal Conditions Application, Organ Transplant Application, Maternal Condition Application and Other Applications for the Years 2014, 2025 & 2030
  • TABLE 170: UK Recent Past, Current & Future Analysis for Synthetic Blood Substitutes by Source - Human Blood Source, Microorganism Based Recombinant HB Source, Synthetic Polymers Source, Stem Cells Source and Other Sources - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 171: UK Historic Review for Synthetic Blood Substitutes by Source - Human Blood Source, Microorganism Based Recombinant HB Source, Synthetic Polymers Source, Stem Cells Source and Other Sources Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
  • TABLE 172: UK 16-Year Perspective for Synthetic Blood Substitutes by Source - Percentage Breakdown of Value Sales for Human Blood Source, Microorganism Based Recombinant HB Source, Synthetic Polymers Source, Stem Cells Source and Other Sources for the Years 2014, 2025 & 2030
• SPAIN
  • TABLE 173: Spain Recent Past, Current & Future Analysis for Synthetic Blood Substitutes by Product - Hemoglobin-based Oxygen Carriers, Perfluorocarbon Emulsions, Stem Cell-Derived Red Blood Cells and Other Products - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 174: Spain Historic Review for Synthetic Blood Substitutes by Product - Hemoglobin-based Oxygen Carriers, Perfluorocarbon Emulsions, Stem Cell-Derived Red Blood Cells and Other Products Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
  • TABLE 175: Spain 16-Year Perspective for Synthetic Blood Substitutes by Product - Percentage Breakdown of Value Sales for Hemoglobin-based Oxygen Carriers, Perfluorocarbon Emulsions, Stem Cell-Derived Red Blood Cells and Other Products for the Years 2014, 2025 & 2030
  • TABLE 176: Spain Recent Past, Current & Future Analysis for Synthetic Blood Substitutes by Component - Red Blood Cell Substitutes, Platelet Substitutes and Plasma Substitutes - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 177: Spain Historic Review for Synthetic Blood Substitutes by Component - Red Blood Cell Substitutes, Platelet Substitutes and Plasma Substitutes Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
  • TABLE 178: Spain 16-Year Perspective for Synthetic Blood Substitutes by Component - Percentage Breakdown of Value Sales for Red Blood Cell Substitutes, Platelet Substitutes and Plasma Substitutes for the Years 2014, 2025 & 2030
  • TABLE 179: Spain Recent Past, Current & Future Analysis for Synthetic Blood Substitutes by Application - Cardiovascular Disease Application, Malignant Neoplasma Application, Injuries Application, Neonatal Conditions Application, Organ Transplant Application, Maternal Condition Application and Other Applications - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 180: Spain Historic Review for Synthetic Blood Substitutes by Application - Cardiovascular Disease Application, Malignant Neoplasma Application, Injuries Application, Neonatal Conditions Application, Organ Transplant Application, Maternal Condition Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
  • TABLE 181: Spain 16-Year Perspective for Synthetic Blood Substitutes by Application - Percentage Breakdown of Value Sales for Cardiovascular Disease Application, Malignant Neoplasma Application, Injuries Application, Neonatal Conditions Application, Organ Transplant Application, Maternal Condition Application and Other Applications for the Years 2014, 2025 & 2030
  • TABLE 182: Spain Recent Past, Current & Future Analysis for Synthetic Blood Substitutes by Source - Human Blood Source, Microorganism Based Recombinant HB Source, Synthetic Polymers Source, Stem Cells Source and Other Sources - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 183: Spain Historic Review for Synthetic Blood Substitutes by Source - Human Blood Source, Microorganism Based Recombinant HB Source, Synthetic Polymers Source, Stem Cells Source and Other Sources Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
  • TABLE 184: Spain 16-Year Perspective for Synthetic Blood Substitutes by Source - Percentage Breakdown of Value Sales for Human Blood Source, Microorganism Based Recombinant HB Source, Synthetic Polymers Source, Stem Cells Source and Other Sources for the Years 2014, 2025 & 2030
• RUSSIA
  • TABLE 185: Russia Recent Past, Current & Future Analysis for Synthetic Blood Substitutes by Product - Hemoglobin-based Oxygen Carriers, Perfluorocarbon Emulsions, Stem Cell-Derived Red Blood Cells and Other Products - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 186: Russia Historic Review for Synthetic Blood Substitutes by Product - Hemoglobin-based Oxygen Carriers, Perfluorocarbon Emulsions, Stem Cell-Derived Red Blood Cells and Other Products Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
  • TABLE 187: Russia 16-Year Perspective for Synthetic Blood Substitutes by Product - Percentage Breakdown of Value Sales for Hemoglobin-based Oxygen Carriers, Perfluorocarbon Emulsions, Stem Cell-Derived Red Blood Cells and Other Products for the Years 2014, 2025 & 2030
  • TABLE 188: Russia Recent Past, Current & Future Analysis for Synthetic Blood Substitutes by Component - Red Blood Cell Substitutes, Platelet Substitutes and Plasma Substitutes - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 189: Russia Historic Review for Synthetic Blood Substitutes by Component - Red Blood Cell Substitutes, Platelet Substitutes and Plasma Substitutes Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
  • TABLE 190: Russia 16-Year Perspective for Synthetic Blood Substitutes by Component - Percentage Breakdown of Value Sales for Red Blood Cell Substitutes, Platelet Substitutes and Plasma Substitutes for the Years 2014, 2025 & 2030
  • TABLE 191: Russia Recent Past, Current & Future Analysis for Synthetic Blood Substitutes by Application - Cardiovascular Disease Application, Malignant Neoplasma Application, Injuries Application, Neonatal Conditions Application, Organ Transplant Application, Maternal Condition Application and Other Applications - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 192: Russia Historic Review for Synthetic Blood Substitutes by Application - Cardiovascular Disease Application, Malignant Neoplasma Application, Injuries Application, Neonatal Conditions Application, Organ Transplant Application, Maternal Condition Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
  • TABLE 193: Russia 16-Year Perspective for Synthetic Blood Substitutes by Application - Percentage Breakdown of Value Sales for Cardiovascular Disease Application, Malignant Neoplasma Application, Injuries Application, Neonatal Conditions Application, Organ Transplant Application, Maternal Condition Application and Other Applications for the Years 2014, 2025 & 2030
  • TABLE 194: Russia Recent Past, Current & Future Analysis for Synthetic Blood Substitutes by Source - Human Blood Source, Microorganism Based Recombinant HB Source, Synthetic Polymers Source, Stem Cells Source and Other Sources - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 195: Russia Historic Review for Synthetic Blood Substitutes by Source - Human Blood Source, Microorganism Based Recombinant HB Source, Synthetic Polymers Source, Stem Cells Source and Other Sources Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
  • TABLE 196: Russia 16-Year Perspective for Synthetic Blood Substitutes by Source - Percentage Breakdown of Value Sales for Human Blood Source, Microorganism Based Recombinant HB Source, Synthetic Polymers Source, Stem Cells Source and Other Sources for the Years 2014, 2025 & 2030
• REST OF EUROPE
  • TABLE 197: Rest of Europe Recent Past, Current & Future Analysis for Synthetic Blood Substitutes by Product - Hemoglobin-based Oxygen Carriers, Perfluorocarbon Emulsions, Stem Cell-Derived Red Blood Cells and Other Products - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 198: Rest of Europe Historic Review for Synthetic Blood Substitutes by Product - Hemoglobin-based Oxygen Carriers, Perfluorocarbon Emulsions, Stem Cell-Derived Red Blood Cells and Other Products Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
  • TABLE 199: Rest of Europe 16-Year Perspective for Synthetic Blood Substitutes by Product - Percentage Breakdown of Value Sales for Hemoglobin-based Oxygen Carriers, Perfluorocarbon Emulsions, Stem Cell-Derived Red Blood Cells and Other Products for the Years 2014, 2025 & 2030
  • TABLE 200: Rest of Europe Recent Past, Current & Future Analysis for Synthetic Blood Substitutes by Component - Red Blood Cell Substitutes, Platelet Substitutes and Plasma Substitutes - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 201: Rest of Europe Historic Review for Synthetic Blood Substitutes by Component - Red Blood Cell Substitutes, Platelet Substitutes and Plasma Substitutes Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
  • TABLE 202: Rest of Europe 16-Year Perspective for Synthetic Blood Substitutes by Component - Percentage Breakdown of Value Sales for Red Blood Cell Substitutes, Platelet Substitutes and Plasma Substitutes for the Years 2014, 2025 & 2030
  • TABLE 203: Rest of Europe Recent Past, Current & Future Analysis for Synthetic Blood Substitutes by Application - Cardiovascular Disease Application, Malignant Neoplasma Application, Injuries Application, Neonatal Conditions Application, Organ Transplant Application, Maternal Condition Application and Other Applications - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 204: Rest of Europe Historic Review for Synthetic Blood Substitutes by Application - Cardiovascular Disease Application, Malignant Neoplasma Application, Injuries Application, Neonatal Conditions Application, Organ Transplant Application, Maternal Condition Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
  • TABLE 205: Rest of Europe 16-Year Perspective for Synthetic Blood Substitutes by Application - Percentage Breakdown of Value Sales for Cardiovascular Disease Application, Malignant Neoplasma Application, Injuries Application, Neonatal Conditions Application, Organ Transplant Application, Maternal Condition Application and Other Applications for the Years 2014, 2025 & 2030
  • TABLE 206: Rest of Europe Recent Past, Current & Future Analysis for Synthetic Blood Substitutes by Source - Human Blood Source, Microorganism Based Recombinant HB Source, Synthetic Polymers Source, Stem Cells Source and Other Sources - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 207: Rest of Europe Historic Review for Synthetic Blood Substitutes by Source - Human Blood Source, Microorganism Based Recombinant HB Source, Synthetic Polymers Source, Stem Cells Source and Other Sources Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
  • TABLE 208: Rest of Europe 16-Year Perspective for Synthetic Blood Substitutes by Source - Percentage Breakdown of Value Sales for Human Blood Source, Microorganism Based Recombinant HB Source, Synthetic Polymers Source, Stem Cells Source and Other Sources for the Years 2014, 2025 & 2030
• ASIA-PACIFIC
  • Synthetic Blood Substitutes Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
  • TABLE 209: Asia-Pacific Recent Past, Current & Future Analysis for Synthetic Blood Substitutes by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
  • TABLE 210: Asia-Pacific Historic Review for Synthetic Blood Substitutes by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
  • TABLE 211: Asia-Pacific 16-Year Perspective for Synthetic Blood Substitutes by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2025 & 2030
  • TABLE 212: Asia-Pacific Recent Past, Current & Future Analysis for Synthetic Blood Substitutes by Product - Hemoglobin-based Oxygen Carriers, Perfluorocarbon Emulsions, Stem Cell-Derived Red Blood Cells and Other Products - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 213: Asia-Pacific Historic Review for Synthetic Blood Substitutes by Product - Hemoglobin-based Oxygen Carriers, Perfluorocarbon Emulsions, Stem Cell-Derived Red Blood Cells and Other Products Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
  • TABLE 214: Asia-Pacific 16-Year Perspective for Synthetic Blood Substitutes by Product - Percentage Breakdown of Value Sales for Hemoglobin-based Oxygen Carriers, Perfluorocarbon Emulsions, Stem Cell-Derived Red Blood Cells and Other Products for the Years 2014, 2025 & 2030
  • TABLE 215: Asia-Pacific Recent Past, Current & Future Analysis for Synthetic Blood Substitutes by Component - Red Blood Cell Substitutes, Platelet Substitutes and Plasma Substitutes - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 216: Asia-Pacific Historic Review for Synthetic Blood Substitutes by Component - Red Blood Cell Substitutes, Platelet Substitutes and Plasma Substitutes Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
  • TABLE 217: Asia-Pacific 16-Year Perspective for Synthetic Blood Substitutes by Component - Percentage Breakdown of Value Sales for Red Blood Cell Substitutes, Platelet Substitutes and Plasma Substitutes for the Years 2014, 2025 & 2030
  • TABLE 218: Asia-Pacific Recent Past, Current & Future Analysis for Synthetic Blood Substitutes by Application - Cardiovascular Disease Application, Malignant Neoplasma Application, Injuries Application, Neonatal Conditions Application, Organ Transplant Application, Maternal Condition Application and Other Applications - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 219: Asia-Pacific Historic Review for Synthetic Blood Substitutes by Application - Cardiovascular Disease Application, Malignant Neoplasma Application, Injuries Application, Neonatal Conditions Application, Organ Transplant Application, Maternal Condition Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
  • TABLE 220: Asia-Pacific 16-Year Perspective for Synthetic Blood Substitutes by Application - Percentage Breakdown of Value Sales for Cardiovascular Disease Application, Malignant Neoplasma Application, Injuries Application, Neonatal Conditions Application, Organ Transplant Application, Maternal Condition Application and Other Applications for the Years 2014, 2025 & 2030
  • TABLE 221: Asia-Pacific Recent Past, Current & Future Analysis for Synthetic Blood Substitutes by Source - Human Blood Source, Microorganism Based Recombinant HB Source, Synthetic Polymers Source, Stem Cells Source and Other Sources - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 222: Asia-Pacific Historic Review for Synthetic Blood Substitutes by Source - Human Blood Source, Microorganism Based Recombinant HB Source, Synthetic Polymers Source, Stem Cells Source and Other Sources Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
  • TABLE 223: Asia-Pacific 16-Year Perspective for Synthetic Blood Substitutes by Source - Percentage Breakdown of Value Sales for Human Blood Source, Microorganism Based Recombinant HB Source, Synthetic Polymers Source, Stem Cells Source and Other Sources for the Years 2014, 2025 & 2030
• AUSTRALIA
  • Synthetic Blood Substitutes Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
  • TABLE 224: Australia Recent Past, Current & Future Analysis for Synthetic Blood Substitutes by Product - Hemoglobin-based Oxygen Carriers, Perfluorocarbon Emulsions, Stem Cell-Derived Red Blood Cells and Other Products - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 225: Australia Historic Review for Synthetic Blood Substitutes by Product - Hemoglobin-based Oxygen Carriers, Perfluorocarbon Emulsions, Stem Cell-Derived Red Blood Cells and Other Products Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
  • TABLE 226: Australia 16-Year Perspective for Synthetic Blood Substitutes by Product - Percentage Breakdown of Value Sales for Hemoglobin-based Oxygen Carriers, Perfluorocarbon Emulsions, Stem Cell-Derived Red Blood Cells and Other Products for the Years 2014, 2025 & 2030
  • TABLE 227: Australia Recent Past, Current & Future Analysis for Synthetic Blood Substitutes by Component - Red Blood Cell Substitutes, Platelet Substitutes and Plasma Substitutes - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 228: Australia Historic Review for Synthetic Blood Substitutes by Component - Red Blood Cell Substitutes, Platelet Substitutes and Plasma Substitutes Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
  • TABLE 229: Australia 16-Year Perspective for Synthetic Blood Substitutes by Component - Percentage Breakdown of Value Sales for Red Blood Cell Substitutes, Platelet Substitutes and Plasma Substitutes for the Years 2014, 2025 & 2030
  • TABLE 230: Australia Recent Past, Current & Future Analysis for Synthetic Blood Substitutes by Application - Cardiovascular Disease Application, Malignant Neoplasma Application, Injuries Application, Neonatal Conditions Application, Organ Transplant Application, Maternal Condition Application and Other Applications - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 231: Australia Historic Review for Synthetic Blood Substitutes by Application - Cardiovascular Disease Application, Malignant Neoplasma Application, Injuries Application, Neonatal Conditions Application, Organ Transplant Application, Maternal Condition Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
  • TABLE 232: Australia 16-Year Perspective for Synthetic Blood Substitutes by Application - Percentage Breakdown of Value Sales for Cardiovascular Disease Application, Malignant Neoplasma Application, Injuries Application, Neonatal Conditions Application, Organ Transplant Application, Maternal Condition Application and Other Applications for the Years 2014, 2025 & 2030
  • TABLE 233: Australia Recent Past, Current & Future Analysis for Synthetic Blood Substitutes by Source - Human Blood Source, Microorganism Based Recombinant HB Source, Synthetic Polymers Source, Stem Cells Source and Other Sources - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 234: Australia Historic Review for Synthetic Blood Substitutes by Source - Human Blood Source, Microorganism Based Recombinant HB Source, Synthetic Polymers Source, Stem Cells Source and Other Sources Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
  • TABLE 235: Australia 16-Year Perspective for Synthetic Blood Substitutes by Source - Percentage Breakdown of Value Sales for Human Blood Source, Microorganism Based Recombinant HB Source, Synthetic Polymers Source, Stem Cells Source and Other Sources for the Years 2014, 2025 & 2030
• INDIA
  • Synthetic Blood Substitutes Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
  • TABLE 236: India Recent Past, Current & Future Analysis for Synthetic Blood Substitutes by Product - Hemoglobin-based Oxygen Carriers, Perfluorocarbon Emulsions, Stem Cell-Derived Red Blood Cells and Other Products - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 237: India Historic Review for Synthetic Blood Substitutes by Product - Hemoglobin-based Oxygen Carriers, Perfluorocarbon Emulsions, Stem Cell-Derived Red Blood Cells and Other Products Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
  • TABLE 238: India 16-Year Perspective for Synthetic Blood Substitutes by Product - Percentage Breakdown of Value Sales for Hemoglobin-based Oxygen Carriers, Perfluorocarbon Emulsions, Stem Cell-Derived Red Blood Cells and Other Products for the Years 2014, 2025 & 2030
  • TABLE 239: India Recent Past, Current & Future Analysis for Synthetic Blood Substitutes by Component - Red Blood Cell Substitutes, Platelet Substitutes and Plasma Substitutes - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 240: India Historic Review for Synthetic Blood Substitutes by Component - Red Blood Cell Substitutes, Platelet Substitutes and Plasma Substitutes Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
  • TABLE 241: India 16-Year Perspective for Synthetic Blood Substitutes by Component - Percentage Breakdown of Value Sales for Red Blood Cell Substitutes, Platelet Substitutes and Plasma Substitutes for the Years 2014, 2025 & 2030
  • TABLE 242: India Recent Past, Current & Future Analysis for Synthetic Blood Substitutes by Application - Cardiovascular Disease Application, Malignant Neoplasma Application, Injuries Application, Neonatal Conditions Application, Organ Transplant Application, Maternal Condition Application and Other Applications - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 243: India Historic Review for Synthetic Blood Substitutes by Application - Cardiovascular Disease Application, Malignant Neoplasma Application, Injuries Application, Neonatal Conditions Application, Organ Transplant Application, Maternal Condition Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
  • TABLE 244: India 16-Year Perspective for Synthetic Blood Substitutes by Application - Percentage Breakdown of Value Sales for Cardiovascular Disease Application, Malignant Neoplasma Application, Injuries Application, Neonatal Conditions Application, Organ Transplant Application, Maternal Condition Application and Other Applications for the Years 2014, 2025 & 2030
  • TABLE 245: India Recent Past, Current & Future Analysis for Synthetic Blood Substitutes by Source - Human Blood Source, Microorganism Based Recombinant HB Source, Synthetic Polymers Source, Stem Cells Source and Other Sources - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 246: India Historic Review for Synthetic Blood Substitutes by Source - Human Blood Source, Microorganism Based Recombinant HB Source, Synthetic Polymers Source, Stem Cells Source and Other Sources Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
  • TABLE 247: India 16-Year Perspective for Synthetic Blood Substitutes by Source - Percentage Breakdown of Value Sales for Human Blood Source, Microorganism Based Recombinant HB Source, Synthetic Polymers Source, Stem Cells Source and Other Sources for the Years 2014, 2025 & 2030
• SOUTH KOREA
  • TABLE 248: South Korea Recent Past, Current & Future Analysis for Synthetic Blood Substitutes by Product - Hemoglobin-based Oxygen Carriers, Perfluorocarbon Emulsions, Stem Cell-Derived Red Blood Cells and Other Products - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 249: South Korea Historic Review for Synthetic Blood Substitutes by Product - Hemoglobin-based Oxygen Carriers, Perfluorocarbon Emulsions, Stem Cell-Derived Red Blood Cells and Other Products Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
  • TABLE 250: South Korea 16-Year Perspective for Synthetic Blood Substitutes by Product - Percentage Breakdown of Value Sales for Hemoglobin-based Oxygen Carriers, Perfluorocarbon Emulsions, Stem Cell-Derived Red Blood Cells and Other Products for the Years 2014, 2025 & 2030
  • TABLE 251: South Korea Recent Past, Current & Future Analysis for Synthetic Blood Substitutes by Component - Red Blood Cell Substitutes, Platelet Substitutes and Plasma Substitutes - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 252: South Korea Historic Review for Synthetic Blood Substitutes by Component - Red Blood Cell Substitutes, Platelet Substitutes and Plasma Substitutes Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
  • TABLE 253: South Korea 16-Year Perspective for Synthetic Blood Substitutes by Component - Percentage Breakdown of Value Sales for Red Blood Cell Substitutes, Platelet Substitutes and Plasma Substitutes for the Years 2014, 2025 & 2030
  • TABLE 254: South Korea Recent Past, Current & Future Analysis for Synthetic Blood Substitutes by Application - Cardiovascular Disease Application, Malignant Neoplasma Application, Injuries Application, Neonatal Conditions Application, Organ Transplant Application, Maternal Condition Application and Other Applications - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 255: South Korea Historic Review for Synthetic Blood Substitutes by Application - Cardiovascular Disease Application, Malignant Neoplasma Application, Injuries Application, Neonatal Conditions Application, Organ Transplant Application, Maternal Condition Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
  • TABLE 256: South Korea 16-Year Perspective for Synthetic Blood Substitutes by Application - Percentage Breakdown of Value Sales for Cardiovascular Disease Application, Malignant Neoplasma Application, Injuries Application, Neonatal Conditions Application, Organ Transplant Application, Maternal Condition Application and Other Applications for the Years 2014, 2025 & 2030
  • TABLE 257: South Korea Recent Past, Current & Future Analysis for Synthetic Blood Substitutes by Source - Human Blood Source, Microorganism Based Recombinant HB Source, Synthetic Polymers Source, Stem Cells Source and Other Sources - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 258: South Korea Historic Review for Synthetic Blood Substitutes by Source - Human Blood Source, Microorganism Based Recombinant HB Source, Synthetic Polymers Source, Stem Cells Source and Other Sources Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
  • TABLE 259: South Korea 16-Year Perspective for Synthetic Blood Substitutes by Source - Percentage Breakdown of Value Sales for Human Blood Source, Microorganism Based Recombinant HB Source, Synthetic Polymers Source, Stem Cells Source and Other Sources for the Years 2014, 2025 & 2030
• REST OF ASIA-PACIFIC
  • TABLE 260: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Synthetic Blood Substitutes by Product - Hemoglobin-based Oxygen Carriers, Perfluorocarbon Emulsions, Stem Cell-Derived Red Blood Cells and Other Products - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 261: Rest of Asia-Pacific Historic Review for Synthetic Blood Substitutes by Product - Hemoglobin-based Oxygen Carriers, Perfluorocarbon Emulsions, Stem Cell-Derived Red Blood Cells and Other Products Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
  • TABLE 262: Rest of Asia-Pacific 16-Year Perspective for Synthetic Blood Substitutes by Product - Percentage Breakdown of Value Sales for Hemoglobin-based Oxygen Carriers, Perfluorocarbon Emulsions, Stem Cell-Derived Red Blood Cells and Other Products for the Years 2014, 2025 & 2030
  • TABLE 263: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Synthetic Blood Substitutes by Component - Red Blood Cell Substitutes, Platelet Substitutes and Plasma Substitutes - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 264: Rest of Asia-Pacific Historic Review for Synthetic Blood Substitutes by Component - Red Blood Cell Substitutes, Platelet Substitutes and Plasma Substitutes Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
  • TABLE 265: Rest of Asia-Pacific 16-Year Perspective for Synthetic Blood Substitutes by Component - Percentage Breakdown of Value Sales for Red Blood Cell Substitutes, Platelet Substitutes and Plasma Substitutes for the Years 2014, 2025 & 2030
  • TABLE 266: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Synthetic Blood Substitutes by Application - Cardiovascular Disease Application, Malignant Neoplasma Application, Injuries Application, Neonatal Conditions Application, Organ Transplant Application, Maternal Condition Application and Other Applications - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 267: Rest of Asia-Pacific Historic Review for Synthetic Blood Substitutes by Application - Cardiovascular Disease Application, Malignant Neoplasma Application, Injuries Application, Neonatal Conditions Application, Organ Transplant Application, Maternal Condition Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
  • TABLE 268: Rest of Asia-Pacific 16-Year Perspective for Synthetic Blood Substitutes by Application - Percentage Breakdown of Value Sales for Cardiovascular Disease Application, Malignant Neoplasma Application, Injuries Application, Neonatal Conditions Application, Organ Transplant Application, Maternal Condition Application and Other Applications for the Years 2014, 2025 & 2030
  • TABLE 269: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Synthetic Blood Substitutes by Source - Human Blood Source, Microorganism Based Recombinant HB Source, Synthetic Polymers Source, Stem Cells Source and Other Sources - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 270: Rest of Asia-Pacific Historic Review for Synthetic Blood Substitutes by Source - Human Blood Source, Microorganism Based Recombinant HB Source, Synthetic Polymers Source, Stem Cells Source and Other Sources Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
  • TABLE 271: Rest of Asia-Pacific 16-Year Perspective for Synthetic Blood Substitutes by Source - Percentage Breakdown of Value Sales for Human Blood Source, Microorganism Based Recombinant HB Source, Synthetic Polymers Source, Stem Cells Source and Other Sources for the Years 2014, 2025 & 2030
• LATIN AMERICA
  • Synthetic Blood Substitutes Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
  • TABLE 272: Latin America Recent Past, Current & Future Analysis for Synthetic Blood Substitutes by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
  • TABLE 273: Latin America Historic Review for Synthetic Blood Substitutes by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
  • TABLE 274: Latin America 16-Year Perspective for Synthetic Blood Substitutes by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2025 & 2030
  • TABLE 275: Latin America Recent Past, Current & Future Analysis for Synthetic Blood Substitutes by Product - Hemoglobin-based Oxygen Carriers, Perfluorocarbon Emulsions, Stem Cell-Derived Red Blood Cells and Other Products - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 276: Latin America Historic Review for Synthetic Blood Substitutes by Product - Hemoglobin-based Oxygen Carriers, Perfluorocarbon Emulsions, Stem Cell-Derived Red Blood Cells and Other Products Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
  • TABLE 277: Latin America 16-Year Perspective for Synthetic Blood Substitutes by Product - Percentage Breakdown of Value Sales for Hemoglobin-based Oxygen Carriers, Perfluorocarbon Emulsions, Stem Cell-Derived Red Blood Cells and Other Products for the Years 2014, 2025 & 2030
  • TABLE 278: Latin America Recent Past, Current & Future Analysis for Synthetic Blood Substitutes by Component - Red Blood Cell Substitutes, Platelet Substitutes and Plasma Substitutes - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 279: Latin America Historic Review for Synthetic Blood Substitutes by Component - Red Blood Cell Substitutes, Platelet Substitutes and Plasma Substitutes Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
  • TABLE 280: Latin America 16-Year Perspective for Synthetic Blood Substitutes by Component - Percentage Breakdown of Value Sales for Red Blood Cell Substitutes, Platelet Substitutes and Plasma Substitutes for the Years 2014, 2025 & 2030
  • TABLE 281: Latin America Recent Past, Current & Future Analysis for Synthetic Blood Substitutes by Application - Cardiovascular Disease Application, Malignant Neoplasma Application, Injuries Application, Neonatal Conditions Application, Organ Transplant Application, Maternal Condition Application and Other Applications - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 282: Latin America Historic Review for Synthetic Blood Substitutes by Application - Cardiovascular Disease Application, Malignant Neoplasma Application, Injuries Application, Neonatal Conditions Application, Organ Transplant Application, Maternal Condition Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
  • TABLE 283: Latin America 16-Year Perspective for Synthetic Blood Substitutes by Application - Percentage Breakdown of Value Sales for Cardiovascular Disease Application, Malignant Neoplasma Application, Injuries Application, Neonatal Conditions Application, Organ Transplant Application, Maternal Condition Application and Other Applications for the Years 2014, 2025 & 2030
  • TABLE 284: Latin America Recent Past, Current & Future Analysis for Synthetic Blood Substitutes by Source - Human Blood Source, Microorganism Based Recombinant HB Source, Synthetic Polymers Source, Stem Cells Source and Other Sources - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 285: Latin America Historic Review for Synthetic Blood Substitutes by Source - Human Blood Source, Microorganism Based Recombinant HB Source, Synthetic Polymers Source, Stem Cells Source and Other Sources Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
  • TABLE 286: Latin America 16-Year Perspective for Synthetic Blood Substitutes by Source - Percentage Breakdown of Value Sales for Human Blood Source, Microorganism Based Recombinant HB Source, Synthetic Polymers Source, Stem Cells Source and Other Sources for the Years 2014, 2025 & 2030
• ARGENTINA
  • TABLE 287: Argentina Recent Past, Current & Future Analysis for Synthetic Blood Substitutes by Product - Hemoglobin-based Oxygen Carriers, Perfluorocarbon Emulsions, Stem Cell-Derived Red Blood Cells and Other Products - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 288: Argentina Historic Review for Synthetic Blood Substitutes by Product - Hemoglobin-based Oxygen Carriers, Perfluorocarbon Emulsions, Stem Cell-Derived Red Blood Cells and Other Products Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
  • TABLE 289: Argentina 16-Year Perspective for Synthetic Blood Substitutes by Product - Percentage Breakdown of Value Sales for Hemoglobin-based Oxygen Carriers, Perfluorocarbon Emulsions, Stem Cell-Derived Red Blood Cells and Other Products for the Years 2014, 2025 & 2030
  • TABLE 290: Argentina Recent Past, Current & Future Analysis for Synthetic Blood Substitutes by Component - Red Blood Cell Substitutes, Platelet Substitutes and Plasma Substitutes - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 291: Argentina Historic Review for Synthetic Blood Substitutes by Component - Red Blood Cell Substitutes, Platelet Substitutes and Plasma Substitutes Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
  • TABLE 292: Argentina 16-Year Perspective for Synthetic Blood Substitutes by Component - Percentage Breakdown of Value Sales for Red Blood Cell Substitutes, Platelet Substitutes and Plasma Substitutes for the Years 2014, 2025 & 2030
  • TABLE 293: Argentina Recent Past, Current & Future Analysis for Synthetic Blood Substitutes by Application - Cardiovascular Disease Application, Malignant Neoplasma Application, Injuries Application, Neonatal Conditions Application, Organ Transplant Application, Maternal Condition Application and Other Applications - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 294: Argentina Historic Review for Synthetic Blood Substitutes by Application - Cardiovascular Disease Application, Malignant Neoplasma Application, Injuries Application, Neonatal Conditions Application, Organ Transplant Application, Maternal Condition Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
  • TABLE 295: Argentina 16-Year Perspective for Synthetic Blood Substitutes by Application - Percentage Breakdown of Value Sales for Cardiovascular Disease Application, Malignant Neoplasma Application, Injuries Application, Neonatal Conditions Application, Organ Transplant Application, Maternal Condition Application and Other Applications for the Years 2014, 2025 & 2030
  • TABLE 296: Argentina Recent Past, Current & Future Analysis for Synthetic Blood Substitutes by Source - Human Blood Source, Microorganism Based Recombinant HB Source, Synthetic Polymers Source, Stem Cells Source and Other Sources - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 297: Argentina Historic Review for Synthetic Blood Substitutes by Source - Human Blood Source, Microorganism Based Recombinant HB Source, Synthetic Polymers Source, Stem Cells Source and Other Sources Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
  • TABLE 298: Argentina 16-Year Perspective for Synthetic Blood Substitutes by Source - Percentage Breakdown of Value Sales for Human Blood Source, Microorganism Based Recombinant HB Source, Synthetic Polymers Source, Stem Cells Source and Other Sources for the Years 2014, 2025 & 2030
• BRAZIL
  • TABLE 299: Brazil Recent Past, Current & Future Analysis for Synthetic Blood Substitutes by Product - Hemoglobin-based Oxygen Carriers, Perfluorocarbon Emulsions, Stem Cell-Derived Red Blood Cells and Other Products - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 300: Brazil Historic Review for Synthetic Blood Substitutes by Product - Hemoglobin-based Oxygen Carriers, Perfluorocarbon Emulsions, Stem Cell-Derived Red Blood Cells and Other Products Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
  • TABLE 301: Brazil 16-Year Perspective for Synthetic Blood Substitutes by Product - Percentage Breakdown of Value Sales for Hemoglobin-based Oxygen Carriers, Perfluorocarbon Emulsions, Stem Cell-Derived Red Blood Cells and Other Products for the Years 2014, 2025 & 2030
  • TABLE 302: Brazil Recent Past, Current & Future Analysis for Synthetic Blood Substitutes by Component - Red Blood Cell Substitutes, Platelet Substitutes and Plasma Substitutes - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 303: Brazil Historic Review for Synthetic Blood Substitutes by Component - Red Blood Cell Substitutes, Platelet Substitutes and Plasma Substitutes Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
  • TABLE 304: Brazil 16-Year Perspective for Synthetic Blood Substitutes by Component - Percentage Breakdown of Value Sales for Red Blood Cell Substitutes, Platelet Substitutes and Plasma Substitutes for the Years 2014, 2025 & 2030
  • TABLE 305: Brazil Recent Past, Current & Future Analysis for Synthetic Blood Substitutes by Application - Cardiovascular Disease Application, Malignant Neoplasma Application, Injuries Application, Neonatal Conditions Application, Organ Transplant Application, Maternal Condition Application and Other Applications - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 306: Brazil Historic Review for Synthetic Blood Substitutes by Application - Cardiovascular Disease Application, Malignant Neoplasma Application, Injuries Application, Neonatal Conditions Application, Organ Transplant Application, Maternal Condition Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
  • TABLE 307: Brazil 16-Year Perspective for Synthetic Blood Substitutes by Application - Percentage Breakdown of Value Sales for Cardiovascular Disease Application, Malignant Neoplasma Application, Injuries Application, Neonatal Conditions Application, Organ Transplant Application, Maternal Condition Application and Other Applications for the Years 2014, 2025 & 2030
  • TABLE 308: Brazil Recent Past, Current & Future Analysis for Synthetic Blood Substitutes by Source - Human Blood Source, Microorganism Based Recombinant HB Source, Synthetic Polymers Source, Stem Cells Source and Other Sources - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 309: Brazil Historic Review for Synthetic Blood Substitutes by Source - Human Blood Source, Microorganism Based Recombinant HB Source, Synthetic Polymers Source, Stem Cells Source and Other Sources Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
  • TABLE 310: Brazil 16-Year Perspective for Synthetic Blood Substitutes by Source - Percentage Breakdown of Value Sales for Human Blood Source, Microorganism Based Recombinant HB Source, Synthetic Polymers Source, Stem Cells Source and Other Sources for the Years 2014, 2025 & 2030
• MEXICO
  • TABLE 311: Mexico Recent Past, Current & Future Analysis for Synthetic Blood Substitutes by Product - Hemoglobin-based Oxygen Carriers, Perfluorocarbon Emulsions, Stem Cell-Derived Red Blood Cells and Other Products - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 312: Mexico Historic Review for Synthetic Blood Substitutes by Product - Hemoglobin-based Oxygen Carriers, Perfluorocarbon Emulsions, Stem Cell-Derived Red Blood Cells and Other Products Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
  • TABLE 313: Mexico 16-Year Perspective for Synthetic Blood Substitutes by Product - Percentage Breakdown of Value Sales for Hemoglobin-based Oxygen Carriers, Perfluorocarbon Emulsions, Stem Cell-Derived Red Blood Cells and Other Products for the Years 2014, 2025 & 2030
  • TABLE 314: Mexico Recent Past, Current & Future Analysis for Synthetic Blood Substitutes by Component - Red Blood Cell Substitutes, Platelet Substitutes and Plasma Substitutes - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 315: Mexico Historic Review for Synthetic Blood Substitutes by Component - Red Blood Cell Substitutes, Platelet Substitutes and Plasma Substitutes Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
  • TABLE 316: Mexico 16-Year Perspective for Synthetic Blood Substitutes by Component - Percentage Breakdown of Value Sales for Red Blood Cell Substitutes, Platelet Substitutes and Plasma Substitutes for the Years 2014, 2025 & 2030
  • TABLE 317: Mexico Recent Past, Current & Future Analysis for Synthetic Blood Substitutes by Application - Cardiovascular Disease Application, Malignant Neoplasma Application, Injuries Application, Neonatal Conditions Application, Organ Transplant Application, Maternal Condition Application and Other Applications - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 318: Mexico Historic Review for Synthetic Blood Substitutes by Application - Cardiovascular Disease Application, Malignant Neoplasma Application, Injuries Application, Neonatal Conditions Application, Organ Transplant Application, Maternal Condition Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
  • TABLE 319: Mexico 16-Year Perspective for Synthetic Blood Substitutes by Application - Percentage Breakdown of Value Sales for Cardiovascular Disease Application, Malignant Neoplasma Application, Injuries Application, Neonatal Conditions Application, Organ Transplant Application, Maternal Condition Application and Other Applications for the Years 2014, 2025 & 2030
  • TABLE 320: Mexico Recent Past, Current & Future Analysis for Synthetic Blood Substitutes by Source - Human Blood Source, Microorganism Based Recombinant HB Source, Synthetic Polymers Source, Stem Cells Source and Other Sources - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 321: Mexico Historic Review for Synthetic Blood Substitutes by Source - Human Blood Source, Microorganism Based Recombinant HB Source, Synthetic Polymers Source, Stem Cells Source and Other Sources Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
  • TABLE 322: Mexico 16-Year Perspective for Synthetic Blood Substitutes by Source - Percentage Breakdown of Value Sales for Human Blood Source, Microorganism Based Recombinant HB Source, Synthetic Polymers Source, Stem Cells Source and Other Sources for the Years 2014, 2025 & 2030
• REST OF LATIN AMERICA
  • TABLE 323: Rest of Latin America Recent Past, Current & Future Analysis for Synthetic Blood Substitutes by Product - Hemoglobin-based Oxygen Carriers, Perfluorocarbon Emulsions, Stem Cell-Derived Red Blood Cells and Other Products - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 324: Rest of Latin America Historic Review for Synthetic Blood Substitutes by Product - Hemoglobin-based Oxygen Carriers, Perfluorocarbon Emulsions, Stem Cell-Derived Red Blood Cells and Other Products Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
  • TABLE 325: Rest of Latin America 16-Year Perspective for Synthetic Blood Substitutes by Product - Percentage Breakdown of Value Sales for Hemoglobin-based Oxygen Carriers, Perfluorocarbon Emulsions, Stem Cell-Derived Red Blood Cells and Other Products for the Years 2014, 2025 & 2030
  • TABLE 326: Rest of Latin America Recent Past, Current & Future Analysis for Synthetic Blood Substitutes by Component - Red Blood Cell Substitutes, Platelet Substitutes and Plasma Substitutes - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 327: Rest of Latin America Historic Review for Synthetic Blood Substitutes by Component - Red Blood Cell Substitutes, Platelet Substitutes and Plasma Substitutes Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
  • TABLE 328: Rest of Latin America 16-Year Perspective for Synthetic Blood Substitutes by Component - Percentage Breakdown of Value Sales for Red Blood Cell Substitutes, Platelet Substitutes and Plasma Substitutes for the Years 2014, 2025 & 2030
  • TABLE 329: Rest of Latin America Recent Past, Current & Future Analysis for Synthetic Blood Substitutes by Application - Cardiovascular Disease Application, Malignant Neoplasma Application, Injuries Application, Neonatal Conditions Application, Organ Transplant Application, Maternal Condition Application and Other Applications - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 330: Rest of Latin America Historic Review for Synthetic Blood Substitutes by Application - Cardiovascular Disease Application, Malignant Neoplasma Application, Injuries Application, Neonatal Conditions Application, Organ Transplant Application, Maternal Condition Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
  • TABLE 331: Rest of Latin America 16-Year Perspective for Synthetic Blood Substitutes by Application - Percentage Breakdown of Value Sales for Cardiovascular Disease Application, Malignant Neoplasma Application, Injuries Application, Neonatal Conditions Application, Organ Transplant Application, Maternal Condition Application and Other Applications for the Years 2014, 2025 & 2030
  • TABLE 332: Rest of Latin America Recent Past, Current & Future Analysis for Synthetic Blood Substitutes by Source - Human Blood Source, Microorganism Based Recombinant HB Source, Synthetic Polymers Source, Stem Cells Source and Other Sources - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 333: Rest of Latin America Historic Review for Synthetic Blood Substitutes by Source - Human Blood Source, Microorganism Based Recombinant HB Source, Synthetic Polymers Source, Stem Cells Source and Other Sources Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
  • TABLE 334: Rest of Latin America 16-Year Perspective for Synthetic Blood Substitutes by Source - Percentage Breakdown of Value Sales for Human Blood Source, Microorganism Based Recombinant HB Source, Synthetic Polymers Source, Stem Cells Source and Other Sources for the Years 2014, 2025 & 2030
• MIDDLE EAST
  • Synthetic Blood Substitutes Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
  • TABLE 335: Middle East Recent Past, Current & Future Analysis for Synthetic Blood Substitutes by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
  • TABLE 336: Middle East Historic Review for Synthetic Blood Substitutes by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
  • TABLE 337: Middle East 16-Year Perspective for Synthetic Blood Substitutes by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2025 & 2030
  • TABLE 338: Middle East Recent Past, Current & Future Analysis for Synthetic Blood Substitutes by Product - Hemoglobin-based Oxygen Carriers, Perfluorocarbon Emulsions, Stem Cell-Derived Red Blood Cells and Other Products - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 339: Middle East Historic Review for Synthetic Blood Substitutes by Product - Hemoglobin-based Oxygen Carriers, Perfluorocarbon Emulsions, Stem Cell-Derived Red Blood Cells and Other Products Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
  • TABLE 340: Middle East 16-Year Perspective for Synthetic Blood Substitutes by Product - Percentage Breakdown of Value Sales for Hemoglobin-based Oxygen Carriers, Perfluorocarbon Emulsions, Stem Cell-Derived Red Blood Cells and Other Products for the Years 2014, 2025 & 2030
  • TABLE 341: Middle East Recent Past, Current & Future Analysis for Synthetic Blood Substitutes by Component - Red Blood Cell Substitutes, Platelet Substitutes and Plasma Substitutes - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 342: Middle East Historic Review for Synthetic Blood Substitutes by Component - Red Blood Cell Substitutes, Platelet Substitutes and Plasma Substitutes Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
  • TABLE 343: Middle East 16-Year Perspective for Synthetic Blood Substitutes by Component - Percentage Breakdown of Value Sales for Red Blood Cell Substitutes, Platelet Substitutes and Plasma Substitutes for the Years 2014, 2025 & 2030
  • TABLE 344: Middle East Recent Past, Current & Future Analysis for Synthetic Blood Substitutes by Application - Cardiovascular Disease Application, Malignant Neoplasma Application, Injuries Application, Neonatal Conditions Application, Organ Transplant Application, Maternal Condition Application and Other Applications - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 345: Middle East Historic Review for Synthetic Blood Substitutes by Application - Cardiovascular Disease Application, Malignant Neoplasma Application, Injuries Application, Neonatal Conditions Application, Organ Transplant Application, Maternal Condition Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
  • TABLE 346: Middle East 16-Year Perspective for Synthetic Blood Substitutes by Application - Percentage Breakdown of Value Sales for Cardiovascular Disease Application, Malignant Neoplasma Application, Injuries Application, Neonatal Conditions Application, Organ Transplant Application, Maternal Condition Application and Other Applications for the Years 2014, 2025 & 2030
  • TABLE 347: Middle East Recent Past, Current & Future Analysis for Synthetic Blood Substitutes by Source - Human Blood Source, Microorganism Based Recombinant HB Source, Synthetic Polymers Source, Stem Cells Source and Other Sources - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 348: Middle East Historic Review for Synthetic Blood Substitutes by Source - Human Blood Source, Microorganism Based Recombinant HB Source, Synthetic Polymers Source, Stem Cells Source and Other Sources Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
  • TABLE 349: Middle East 16-Year Perspective for Synthetic Blood Substitutes by Source - Percentage Breakdown of Value Sales for Human Blood Source, Microorganism Based Recombinant HB Source, Synthetic Polymers Source, Stem Cells Source and Other Sources for the Years 2014, 2025 & 2030
• IRAN
  • TABLE 350: Iran Recent Past, Current & Future Analysis for Synthetic Blood Substitutes by Product - Hemoglobin-based Oxygen Carriers, Perfluorocarbon Emulsions, Stem Cell-Derived Red Blood Cells and Other Products - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 351: Iran Historic Review for Synthetic Blood Substitutes by Product - Hemoglobin-based Oxygen Carriers, Perfluorocarbon Emulsions, Stem Cell-Derived Red Blood Cells and Other Products Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
  • TABLE 352: Iran 16-Year Perspective for Synthetic Blood Substitutes by Product - Percentage Breakdown of Value Sales for Hemoglobin-based Oxygen Carriers, Perfluorocarbon Emulsions, Stem Cell-Derived Red Blood Cells and Other Products for the Years 2014, 2025 & 2030
  • TABLE 353: Iran Recent Past, Current & Future Analysis for Synthetic Blood Substitutes by Component - Red Blood Cell Substitutes, Platelet Substitutes and Plasma Substitutes - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 354: Iran Historic Review for Synthetic Blood Substitutes by Component - Red Blood Cell Substitutes, Platelet Substitutes and Plasma Substitutes Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
  • TABLE 355: Iran 16-Year Perspective for Synthetic Blood Substitutes by Component - Percentage Breakdown of Value Sales for Red Blood Cell Substitutes, Platelet Substitutes and Plasma Substitutes for the Years 2014, 2025 & 2030
  • TABLE 356: Iran Recent Past, Current & Future Analysis for Synthetic Blood Substitutes by Application - Cardiovascular Disease Application, Malignant Neoplasma Application, Injuries Application, Neonatal Conditions Application, Organ Transplant Application, Maternal Condition Application and Other Applications - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 357: Iran Historic Review for Synthetic Blood Substitutes by Application - Cardiovascular Disease Application, Malignant Neoplasma Application, Injuries Application, Neonatal Conditions Application, Organ Transplant Application, Maternal Condition Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
  • TABLE 358: Iran 16-Year Perspective for Synthetic Blood Substitutes by Application - Percentage Breakdown of Value Sales for Cardiovascular Disease Application, Malignant Neoplasma Application, Injuries Application, Neonatal Conditions Application, Organ Transplant Application, Maternal Condition Application and Other Applications for the Years 2014, 2025 & 2030
  • TABLE 359: Iran Recent Past, Current & Future Analysis for Synthetic Blood Substitutes by Source - Human Blood Source, Microorganism Based Recombinant HB Source, Synthetic Polymers Source, Stem Cells Source and Other Sources - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 360: Iran Historic Review for Synthetic Blood Substitutes by Source - Human Blood Source, Microorganism Based Recombinant HB Source, Synthetic Polymers Source, Stem Cells Source and Other Sources Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
  • TABLE 361: Iran 16-Year Perspective for Synthetic Blood Substitutes by Source - Percentage Breakdown of Value Sales for Human Blood Source, Microorganism Based Recombinant HB Source, Synthetic Polymers Source, Stem Cells Source and Other Sources for the Years 2014, 2025 & 2030
• ISRAEL
  • TABLE 362: Israel Recent Past, Current & Future Analysis for Synthetic Blood Substitutes by Product - Hemoglobin-based Oxygen Carriers, Perfluorocarbon Emulsions, Stem Cell-Derived Red Blood Cells and Other Products - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 363: Israel Historic Review for Synthetic Blood Substitutes by Product - Hemoglobin-based Oxygen Carriers, Perfluorocarbon Emulsions, Stem Cell-Derived Red Blood Cells and Other Products Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
  • TABLE 364: Israel 16-Year Perspective for Synthetic Blood Substitutes by Product - Percentage Breakdown of Value Sales for Hemoglobin-based Oxygen Carriers, Perfluorocarbon Emulsions, Stem Cell-Derived Red Blood Cells and Other Products for the Years 2014, 2025 & 2030
  • TABLE 365: Israel Recent Past, Current & Future Analysis for Synthetic Blood Substitutes by Component - Red Blood Cell Substitutes, Platelet Substitutes and Plasma Substitutes - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 366: Israel Historic Review for Synthetic Blood Substitutes by Component - Red Blood Cell Substitutes, Platelet Substitutes and Plasma Substitutes Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
  • TABLE 367: Israel 16-Year Perspective for Synthetic Blood Substitutes by Component - Percentage Breakdown of Value Sales for Red Blood Cell Substitutes, Platelet Substitutes and Plasma Substitutes for the Years 2014, 2025 & 2030
  • TABLE 368: Israel Recent Past, Current & Future Analysis for Synthetic Blood Substitutes by Application - Cardiovascular Disease Application, Malignant Neoplasma Application, Injuries Application, Neonatal Conditions Application, Organ Transplant Application, Maternal Condition Application and Other Applications - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 369: Israel Historic Review for Synthetic Blood Substitutes by Application - Cardiovascular Disease Application, Malignant Neoplasma Application, Injuries Application, Neonatal Conditions Application, Organ Transplant Application, Maternal Condition Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
  • TABLE 370: Israel 16-Year Perspective for Synthetic Blood Substitutes by Application - Percentage Breakdown of Value Sales for Cardiovascular Disease Application, Malignant Neoplasma Application, Injuries Application, Neonatal Conditions Application, Organ Transplant Application, Maternal Condition Application and Other Applications for the Years 2014, 2025 & 2030
  • TABLE 371: Israel Recent Past, Current & Future Analysis for Synthetic Blood Substitutes by Source - Human Blood Source, Microorganism Based Recombinant HB Source, Synthetic Polymers Source, Stem Cells Source and Other Sources - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 372: Israel Historic Review for Synthetic Blood Substitutes by Source - Human Blood Source, Microorganism Based Recombinant HB Source, Synthetic Polymers Source, Stem Cells Source and Other Sources Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
  • TABLE 373: Israel 16-Year Perspective for Synthetic Blood Substitutes by Source - Percentage Breakdown of Value Sales for Human Blood Source, Microorganism Based Recombinant HB Source, Synthetic Polymers Source, Stem Cells Source and Other Sources for the Years 2014, 2025 & 2030
• SAUDI ARABIA
  • TABLE 374: Saudi Arabia Recent Past, Current & Future Analysis for Synthetic Blood Substitutes by Product - Hemoglobin-based Oxygen Carriers, Perfluorocarbon Emulsions, Stem Cell-Derived Red Blood Cells and Other Products - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 375: Saudi Arabia Historic Review for Synthetic Blood Substitutes by Product - Hemoglobin-based Oxygen Carriers, Perfluorocarbon Emulsions, Stem Cell-Derived Red Blood Cells and Other Products Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
  • TABLE 376: Saudi Arabia 16-Year Perspective for Synthetic Blood Substitutes by Product - Percentage Breakdown of Value Sales for Hemoglobin-based Oxygen Carriers, Perfluorocarbon Emulsions, Stem Cell-Derived Red Blood Cells and Other Products for the Years 2014, 2025 & 2030
  • TABLE 377: Saudi Arabia Recent Past, Current & Future Analysis for Synthetic Blood Substitutes by Component - Red Blood Cell Substitutes, Platelet Substitutes and Plasma Substitutes - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 378: Saudi Arabia Historic Review for Synthetic Blood Substitutes by Component - Red Blood Cell Substitutes, Platelet Substitutes and Plasma Substitutes Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
  • TABLE 379: Saudi Arabia 16-Year Perspective for Synthetic Blood Substitutes by Component - Percentage Breakdown of Value Sales for Red Blood Cell Substitutes, Platelet Substitutes and Plasma Substitutes for the Years 2014, 2025 & 2030
  • TABLE 380: Saudi Arabia Recent Past, Current & Future Analysis for Synthetic Blood Substitutes by Application - Cardiovascular Disease Application, Malignant Neoplasma Application, Injuries Application, Neonatal Conditions Application, Organ Transplant Application, Maternal Condition Application and Other Applications - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 381: Saudi Arabia Historic Review for Synthetic Blood Substitutes by Application - Cardiovascular Disease Application, Malignant Neoplasma Application, Injuries Application, Neonatal Conditions Application, Organ Transplant Application, Maternal Condition Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
  • TABLE 382: Saudi Arabia 16-Year Perspective for Synthetic Blood Substitutes by Application - Percentage Breakdown of Value Sales for Cardiovascular Disease Application, Malignant Neoplasma Application, Injuries Application, Neonatal Conditions Application, Organ Transplant Application, Maternal Condition Application and Other Applications for the Years 2014, 2025 & 2030
  • TABLE 383: Saudi Arabia Recent Past, Current & Future Analysis for Synthetic Blood Substitutes by Source - Human Blood Source, Microorganism Based Recombinant HB Source, Synthetic Polymers Source, Stem Cells Source and Other Sources - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 384: Saudi Arabia Historic Review for Synthetic Blood Substitutes by Source - Human Blood Source, Microorganism Based Recombinant HB Source, Synthetic Polymers Source, Stem Cells Source and Other Sources Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
  • TABLE 385: Saudi Arabia 16-Year Perspective for Synthetic Blood Substitutes by Source - Percentage Breakdown of Value Sales for Human Blood Source, Microorganism Based Recombinant HB Source, Synthetic Polymers Source, Stem Cells Source and Other Sources for the Years 2014, 2025 & 2030
• UNITED ARAB EMIRATES
  • TABLE 386: UAE Recent Past, Current & Future Analysis for Synthetic Blood Substitutes by Product - Hemoglobin-based Oxygen Carriers, Perfluorocarbon Emulsions, Stem Cell-Derived Red Blood Cells and Other Products - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 387: UAE Historic Review for Synthetic Blood Substitutes by Product - Hemoglobin-based Oxygen Carriers, Perfluorocarbon Emulsions, Stem Cell-Derived Red Blood Cells and Other Products Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
  • TABLE 388: UAE 16-Year Perspective for Synthetic Blood Substitutes by Product - Percentage Breakdown of Value Sales for Hemoglobin-based Oxygen Carriers, Perfluorocarbon Emulsions, Stem Cell-Derived Red Blood Cells and Other Products for the Years 2014, 2025 & 2030
  • TABLE 389: UAE Recent Past, Current & Future Analysis for Synthetic Blood Substitutes by Component - Red Blood Cell Substitutes, Platelet Substitutes and Plasma Substitutes - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 390: UAE Historic Review for Synthetic Blood Substitutes by Component - Red Blood Cell Substitutes, Platelet Substitutes and Plasma Substitutes Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
  • TABLE 391: UAE 16-Year Perspective for Synthetic Blood Substitutes by Component - Percentage Breakdown of Value Sales for Red Blood Cell Substitutes, Platelet Substitutes and Plasma Substitutes for the Years 2014, 2025 & 2030
  • TABLE 392: UAE Recent Past, Current & Future Analysis for Synthetic Blood Substitutes by Application - Cardiovascular Disease Application, Malignant Neoplasma Application, Injuries Application, Neonatal Conditions Application, Organ Transplant Application, Maternal Condition Application and Other Applications - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 393: UAE Historic Review for Synthetic Blood Substitutes by Application - Cardiovascular Disease Application, Malignant Neoplasma Application, Injuries Application, Neonatal Conditions Application, Organ Transplant Application, Maternal Condition Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
  • TABLE 394: UAE 16-Year Perspective for Synthetic Blood Substitutes by Application - Percentage Breakdown of Value Sales for Cardiovascular Disease Application, Malignant Neoplasma Application, Injuries Application, Neonatal Conditions Application, Organ Transplant Application, Maternal Condition Application and Other Applications for the Years 2014, 2025 & 2030
  • TABLE 395: UAE Recent Past, Current & Future Analysis for Synthetic Blood Substitutes by Source - Human Blood Source, Microorganism Based Recombinant HB Source, Synthetic Polymers Source, Stem Cells Source and Other Sources - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 396: UAE Historic Review for Synthetic Blood Substitutes by Source - Human Blood Source, Microorganism Based Recombinant HB Source, Synthetic Polymers Source, Stem Cells Source and Other Sources Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
  • TABLE 397: UAE 16-Year Perspective for Synthetic Blood Substitutes by Source - Percentage Breakdown of Value Sales for Human Blood Source, Microorganism Based Recombinant HB Source, Synthetic Polymers Source, Stem Cells Source and Other Sources for the Years 2014, 2025 & 2030
• REST OF MIDDLE EAST
  • TABLE 398: Rest of Middle East Recent Past, Current & Future Analysis for Synthetic Blood Substitutes by Product - Hemoglobin-based Oxygen Carriers, Perfluorocarbon Emulsions, Stem Cell-Derived Red Blood Cells and Other Products - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 399: Rest of Middle East Historic Review for Synthetic Blood Substitutes by Product - Hemoglobin-based Oxygen Carriers, Perfluorocarbon Emulsions, Stem Cell-Derived Red Blood Cells and Other Products Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
  • TABLE 400: Rest of Middle East 16-Year Perspective for Synthetic Blood Substitutes by Product - Percentage Breakdown of Value Sales for Hemoglobin-based Oxygen Carriers, Perfluorocarbon Emulsions, Stem Cell-Derived Red Blood Cells and Other Products for the Years 2014, 2025 & 2030
  • TABLE 401: Rest of Middle East Recent Past, Current & Future Analysis for Synthetic Blood Substitutes by Component - Red Blood Cell Substitutes, Platelet Substitutes and Plasma Substitutes - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 402: Rest of Middle East Historic Review for Synthetic Blood Substitutes by Component - Red Blood Cell Substitutes, Platelet Substitutes and Plasma Substitutes Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
  • TABLE 403: Rest of Middle East 16-Year Perspective for Synthetic Blood Substitutes by Component - Percentage Breakdown of Value Sales for Red Blood Cell Substitutes, Platelet Substitutes and Plasma Substitutes for the Years 2014, 2025 & 2030
  • TABLE 404: Rest of Middle East Recent Past, Current & Future Analysis for Synthetic Blood Substitutes by Application - Cardiovascular Disease Application, Malignant Neoplasma Application, Injuries Application, Neonatal Conditions Application, Organ Transplant Application, Maternal Condition Application and Other Applications - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 405: Rest of Middle East Historic Review for Synthetic Blood Substitutes by Application - Cardiovascular Disease Application, Malignant Neoplasma Application, Injuries Application, Neonatal Conditions Application, Organ Transplant Application, Maternal Condition Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
  • TABLE 406: Rest of Middle East 16-Year Perspective for Synthetic Blood Substitutes by Application - Percentage Breakdown of Value Sales for Cardiovascular Disease Application, Malignant Neoplasma Application, Injuries Application, Neonatal Conditions Application, Organ Transplant Application, Maternal Condition Application and Other Applications for the Years 2014, 2025 & 2030
  • TABLE 407: Rest of Middle East Recent Past, Current & Future Analysis for Synthetic Blood Substitutes by Source - Human Blood Source, Microorganism Based Recombinant HB Source, Synthetic Polymers Source, Stem Cells Source and Other Sources - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 408: Rest of Middle East Historic Review for Synthetic Blood Substitutes by Source - Human Blood Source, Microorganism Based Recombinant HB Source, Synthetic Polymers Source, Stem Cells Source and Other Sources Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
  • TABLE 409: Rest of Middle East 16-Year Perspective for Synthetic Blood Substitutes by Source - Percentage Breakdown of Value Sales for Human Blood Source, Microorganism Based Recombinant HB Source, Synthetic Polymers Source, Stem Cells Source and Other Sources for the Years 2014, 2025 & 2030
• AFRICA
  • Synthetic Blood Substitutes Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
  • TABLE 410: Africa Recent Past, Current & Future Analysis for Synthetic Blood Substitutes by Product - Hemoglobin-based Oxygen Carriers, Perfluorocarbon Emulsions, Stem Cell-Derived Red Blood Cells and Other Products - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 411: Africa Historic Review for Synthetic Blood Substitutes by Product - Hemoglobin-based Oxygen Carriers, Perfluorocarbon Emulsions, Stem Cell-Derived Red Blood Cells and Other Products Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
  • TABLE 412: Africa 16-Year Perspective for Synthetic Blood Substitutes by Product - Percentage Breakdown of Value Sales for Hemoglobin-based Oxygen Carriers, Perfluorocarbon Emulsions, Stem Cell-Derived Red Blood Cells and Other Products for the Years 2014, 2025 & 2030
  • TABLE 413: Africa Recent Past, Current & Future Analysis for Synthetic Blood Substitutes by Component - Red Blood Cell Substitutes, Platelet Substitutes and Plasma Substitutes - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 414: Africa Historic Review for Synthetic Blood Substitutes by Component - Red Blood Cell Substitutes, Platelet Substitutes and Plasma Substitutes Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
  • TABLE 415: Africa 16-Year Perspective for Synthetic Blood Substitutes by Component - Percentage Breakdown of Value Sales for Red Blood Cell Substitutes, Platelet Substitutes and Plasma Substitutes for the Years 2014, 2025 & 2030
  • TABLE 416: Africa Recent Past, Current & Future Analysis for Synthetic Blood Substitutes by Application - Cardiovascular Disease Application, Malignant Neoplasma Application, Injuries Application, Neonatal Conditions Application, Organ Transplant Application, Maternal Condition Application and Other Applications - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 417: Africa Historic Review for Synthetic Blood Substitutes by Application - Cardiovascular Disease Application, Malignant Neoplasma Application, Injuries Application, Neonatal Conditions Application, Organ Transplant Application, Maternal Condition Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
  • TABLE 418: Africa 16-Year Perspective for Synthetic Blood Substitutes by Application - Percentage Breakdown of Value Sales for Cardiovascular Disease Application, Malignant Neoplasma Application, Injuries Application, Neonatal Conditions Application, Organ Transplant Application, Maternal Condition Application and Other Applications for the Years 2014, 2025 & 2030
  • TABLE 419: Africa Recent Past, Current & Future Analysis for Synthetic Blood Substitutes by Source - Human Blood Source, Microorganism Based Recombinant HB Source, Synthetic Polymers Source, Stem Cells Source and Other Sources - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 420: Africa Historic Review for Synthetic Blood Substitutes by Source - Human Blood Source, Microorganism Based Recombinant HB Source, Synthetic Polymers Source, Stem Cells Source and Other Sources Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
  • TABLE 421: Africa 16-Year Perspective for Synthetic Blood Substitutes by Source - Percentage Breakdown of Value Sales for Human Blood Source, Microorganism Based Recombinant HB Source, Synthetic Polymers Source, Stem Cells Source and Other Sources for the Years 2014, 2025 & 2030

IV. COMPETITION